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ABSTRACT OF DISSERTATION

COMBINATION OF INVESTIGATIONAL CELL-BASED THERAPY
AND DEEP BRAIN STIMULATION TO ALTER THE PROGRESSION OF
PARKINSON’S DISEASE
Parkinson’s disease (PD) is the second most common neurodegenerative disorder
and the motor symptoms are caused by progressive loss of midbrain dopamine neurons.
There is no current treatment that can slow or reverse PD. Our current “DBS-Plus” clinical
trial (NCT02369003) features the implantation in vivo of autologous Schwann cells (SCs)
derived from a patient’s sural nerve into the substantia nigra pars compacta (SNpc) in
combination with Deep Brain Stimulation (DBS) therapy for treating patients with
advanced PD.
The central hypothesis is that transdifferentiated SCs within conditioned nerve tissue
will deliver pro-regenerative factors to enhance the survival of the degenerating
dopaminergic cells in the SNpc. The main goal of our studies is to determine if implantation
of peripheral nerve tissue into SNpc in combination with DBS surgeries is safe, feasible
and can possibly slow the loss of the midbrain dopamine neurons. First, RNA sequencing
was used to validate the repair phenotype of human sural nerve tissue two weeks after
transaction injury. The transcriptomic analysis showed that 3641 genes were differentially
expressed in conjunction with the upregulation of multiple neurotrophic factors and the
enhancement of axonogenesis. Secondly, to study the neurobiology of the implant, we
grafted human nerve implant into the dorsal striatum of athymic nude rats (called NeuroAvatars). Immunostaining studies showed a remarkable survival of the implanted human
SCs up to 6 months post-implantation in Neuro-Avatar animals. In addition, there were
significant increases in the numbers of surviving human-derived cells in the NeuroAvatar's using pre-degenerated human sural nerve tissue as compared to the same sural
nerve tissue that was harvested in its normal state.
Finally, we studied data from 27 human subjects with PD that had received DBS
plus autologous nerve-implants. The safety of the combined intervention and the
progression of the motor symptoms were evaluated at baseline, 12, and 24 months using
the Unified Parkinson’s Disease Rating Scale part III (UPDRS). The safety of the studies

at 2 years post implantation showed adverse events (AE’s) that were similar to those seen
with standard DBS therapy. In addition, there was a significant motor improvement on the
side contralateral to the tissue implantation in comparison to the ipsilateral one. Taken
together, our data support that combining DBS with in vivo pre-degenerated peripheral
nerve tissue containing SCs can serve as a safe and promising disease-modifying therapy
to alter the progression of PD.
KEYWORDS: Schwann cell, Peripheral Nerve, Neurotrophic factor, Deep Brain
Stimulation, Parkinson’s disease
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CHAPTER ONE: INTRODUCTION_UTILIZING PERIPHERAL NERVE
REGENERATIVE ELEMENTS TO REPAIR DAMAGE IN THE CNS

Abstract

An ongoing question in neuroscience is how the peripheral nervous system can
repair itself following an injury or insult whereas the central nervous system has a
profoundly limited ability for repair. The recent and rapid advancement of our
understanding of the gene expression and corresponding biochemical profiles of Schwann
cells, within the distal segments of injured peripheral nerves, has helped elucidate the
potential mechanisms underlying the unique ability for these cells to enable regeneration
of peripheral nerve tissue. Meanwhile, with a new understanding and appreciation for the
capabilities of the peripheral nervous system, we are beginning to unlock the potential for
neural regeneration and repair within the central nervous system. The aim of this
introduction is to briefly outline the historical advancements and the scientific background
that lead to the concept of utilizing peripheral nerve tissue implants or Schwann cell culture
implants to serve as repair mechanisms for the central nervous system in the clinical setting
of spinal cord injury, multiple sclerosis, and neurodegenerative disorders such as
Parkinson’s disease.

El Seblani, N., Welleford, A., Quintero, J. E., van Horne, C., & Gerhardt, G. A. (2020).
Invited Review: Utilizing Peripheral Nerve Regenerative Elements to Repair Damage in
the CNS. Journal of Neuroscience Methods, 108623 (El Seblani, Welleford, Quintero, van
Horne, & Gerhardt, 2020)
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Historical Perspective of Peripheral Nerves and Their Regenerative Capacity in the
Central Nervous System

The interesting and unpredicted finding that peripheral nerves (PN) had the ability
to regenerate was demonstrated in the 1500’s (1596) when a surgeon, Gabriele Ferrara,
published his meticulous technique for suturing together the ends of a transected nerve
following injury (Artico, Cervoni, Nucci, & Giuffre, 1996). Schwann and Schleiden (1847)
later recognized the complexity and dynamic nature of the PN cells (Schwann & Schleiden,
1847). Schwann, in his treatise on cell theory, attempted to clarify the origins and
differences between nerve fibers and their ensheathing components. Schwann offered
several possibilities, including that the nerve fibers formed from the membranous
coalescence of the ensheathing cells. Waller studied and characterized the changes taking
place in the distal PN segment following disruption or transection, but he did not yet have
an electron microscope to truly define the reorganization (Waller, 1850). In 1891, Von
Büngner noted that in the distal segment, Schwann cells (SCs) proliferated and formed
bands along the remaining collagen components (Koeppen, 2004). These bands are now
known as “Bands of Büngner”. Büngner noted that this construct was the key component
allowing the impressive ability of PN to regenerate following injury. It is now understood
that the Bands of Büngner are formed when transdifferentiated SCs change their profile
from myelinating into a phagocytic phenotype first and recruit neutrophils and
macrophages through chemotactic signaling (Lindborg, Mack, & Zigmond, 2017). This
initiates the Wallerian degeneration, which is important to clear the distal stump of axonal
and myelin debris. Transdifferentiated SCs disperse along Bands of Büngner to support
and guide regenerating growth cones.
2

The concept that Wallerian degeneration and Bands of Büngner were important for
nerve repair was understood by some of the early researchers asking questions regarding
neuronal plasticity. One of Cajal’s protégés, Francisco Tello, designed a set of experiments
in 1911 through which he utilized segments of a sciatic nerve implanted into the cortex of
rabbits (TELLO, 1913). The nerve was transected 8-14 days before implanting thus
allowing Wallerian degeneration to occur. Tello found that predegenerated PN grafts could
promote CNS regeneration and postulated that the release of neurotrophic substances from
PN cells played a key role. Cajal later used a microscope and was able to better define not
only the degenerative changes but also the regenerative potential of PN. While commenting
on his findings in 1928, Cajal noted that the CNS fibers acted as if “they were attracted by
an irresistible force” (Cajal, 1928).

Technical signs of progress revitalize the concept of using peripheral nerve implants
In the early eighties, Aguayo and his colleagues’ pioneering work with PNS and
CNS regeneration

has encouraged other investigators to design different grafting

techniques to test how the PN environment augments the capacity of CNS neurons to
regenerate and grow new fibers (Aguayo, Björklund, Stenevi, & Carlstedt, 1984; Bray,
David, Carlstedt, & Aguayo, 1983; Kao, Chang, & Bloodworth Jr, 1977). In addition to
validating the ability of central axons to regenerate along the PN graft, they observed that
such regeneration is dependent on the distance between the central neuron cell body and
the graft location (Richardson & Issa, 1984).
Axonal regeneration and elongation in response to grafted PN tissue can occur in
cortical as well as in subcortical areas. Grafting a segment of the sciatic nerve into the basal
3

ganglia and the cortex of rats showed that the largest number of neurons grew from the
striatum (Benfey & Aguayo, 1982). Such an observation indicated that the striatal cells are
able to regenerate and extend new axons when they are in a close proximity to the PN
grafts.
The remarkable collaboration between Aguayo, Björklund, Stenevi, and Carlstedt
resulted in a finding that highlighted the potential of PN grafts in supporting the viability
and regeneration of the central neurons in disease states (Aguayo et al., 1984; Gage et al.,
1985). Their animal experiments were undertaken in two stages. In stage I: The
dopaminergic cells of the striatum were depleted by 6-hydroxydopamine (6-OHDA), a
state analogous to the striatum pathology in Parkinson’s disease (PD), and grafted with
mesencephalic rat fetal tissue over the superior colliculus. Then, an approximate 2 cm
segment of heterologous sciatic nerve was placed in the skull. One end of the nerve was
connected to the mesencephalic graft, while the other nerve end was left freely hanging
over the frontal bone. In stage II, two months after stage I, the nerve end over the frontal
bone was transected and the freshly cut free end was inserted into the already depleted
dorsal striatum. Five months after implantation, the immunohistochemical staining for
tyrosine hydroxylase (TH), the rate-limiting enzyme for dopamine synthesis, showed that
the PN grafts were able to support the survival and extension of the axons from the remotely
implanted fetal mesencephalic neurons into the adult rat striatum. This experiment strongly
validated that PN grafts have the capacity to promote fetal neuron survival, axonal
regeneration, and guidance, noted that non-neuronal cells that were known to be supportive
of PNS repair were also essential for the growth of axons from the transplanted cells into
the CNS.

4

The critical role of these non-neuronal cells was highlighted in Anderson’s work
which demonstrated how nerve axonal growth into freeze-dried PN grafts was suspended
until SCs invaded the grafts (Anderson et al., 1983). SCs secrete neurotrophic factors in
the first few days following the nerve injury and have been shown to induce cholinergic
neuron sprouting in vivo (Carey & Bunge, 1981; Manthorpe et al., 1983). Furthermore,
examination of the PN grafts at different time intervals up to 12 months posttransplantation of long nerves into the CNS confirmed that the PN tissue survives and
myelinates CNS axons (Munz, Rasminsky, Aguayo, Vidal-Sanz, & Devor, 1985).
Meanwhile, Ebner, Erzurumlu, and Lee recognized the importance of PNS injury
signals in augmenting the viability and the regenerative capacity of implanted embryonic
cells within

adult brain environment (Ebner, Erzurumlu, & Lee, 1989). In their

experiments, they grafted embryonic neocortical cells into the rat cortex of topographically
injured sensory nerve and measured the extent of the specific thalamic fiber ingrowth and
activation in the implanted cells. Interestingly, they found that introducing what they called
a “conditioning lesion” of the PN resulted in an extensive growth and later a functional
innervation of the implant. Basically, their research raised the question of how damage to
a PN enhances the regenerative capacity of the central neurons several synapses away. One
of their main explanations for that observation was that lesioned PN tissue releases growth
signals and molecules which were transported retrogradely to the distant brain neurons to
enhance their survival and regeneration. They were able to physiologically record, at 35
days after grafting, spontaneous and organized discharges of action potentials within the
implant. Additionally, they demonstrated the growth of thalamic fibers and their terminals
into the grafts using anterograde horseradish peroxidase staining. Hence, their work

5

supported that the CNS has, in fact, a regenerative capacity that could be unleashed in
response to a specific stimulus and the PNS milieu can be a source for such a stimulus in
the CNS.
The regenerative interaction between PN and the CNS was also described in a set
of elegant experiments by Chi and Dahl who grafted an autologous sciatic nerve into the
rat CNS (Chi and Dahl, 1983). They performed the transplantation using two techniques.
The first technique was called the “through-and-through” model during which a segment
of the sciatic nerve was passed through two craniotomy holes. The second technique was
a “nerve-within-tube” model during which a small tube of polyethylene containing a nerve
piece was implanted in the rat CNS. Axonal sprouting from brain tissue to the nerve in the
“nerve-within-tube” model started as early as 2 weeks post-grafting and was characterized
by a slow-moving and organized pattern of axonal regeneration. In comparison, the axons
in the “through-and-through” model followed a disorganized and tortuous type of
regeneration. That could be a result of different CNS axons exiting the graft and entering
the brain tissue from the sides. Chi and Dahl also noticed that the axonal fibers in the
“nerve-within-tube” model were able to grow from the brain into the graft with less damage
to the brain. Remarkably, they identified “reacting” SCs secreting a unique type of Glial
Fibrillary Acidic Protein (GFAP) throughout the graft. On average, the nerve grafts
survived longer with the “through-and-through” model (up to 6 months) in comparison to
the nerve-within-tube model (2 months). Regeneration of the non-myelinated axons of the
brain tissue was observed around 1 month while that of the myelinated fibers was not
observed before 3 months. Central gliosis did not prevent the axonal regeneration but
affected the orientation of the new axonal fibers. The grafts that completely faced the brain
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tissue were well innervated by new axons, which supported the idea that PN tissue has the
potential to induce formation and regeneration of axons in the CNS.
Interestingly, implantation of a PN in rat brain induces the formation of fenestrated
capillaries within the graft after 5 weeks and myelinated and non-myelinated axons in the
implant 8 weeks after implantation (Mitchell, Stauber, Anderson, & Mayor, 1985). In their
attempt to trace the source of the regenerating axons, Mitchell and his colleagues used a
fluorochrome true blue label, which labeled the cortical areas adjacent to the graft in
addition to the ipsilateral trigeminal and superior cervical ganglia. The authors could not
trace the dye to distant CNS areas and concluded that the bulk of the regenerating axons
originated from pial nerves. Nevertheless, the ability of the central neurons to regenerate
their axons for a significant distance in an injured CNS environment had been thoroughly
demonstrated by other research groups (Katzman, Björklund, Owman, Stenevi, & West,
1971). Björklund and his team, observed that catecholamine fibers were able to sprout after
iris tissue was grafted into injured rat brain.
In response to an axonal damage, CNS neuronal cell bodies are at a great risk for
chromatolysis and retrograde death. Villegas-Perez demonstrated the potential of tibial
nerve graft to significantly preserve axotomized retinal ganglionic cells (Villegas-Perez,
Vidal-Sanz, Bray, & Aguayo, 1988) . In addition, they showed that the PN graft guided the
regenerating axons to synapse with the appropriate CNS targets instead of randomly
synapsing in the injured CNS. Yet, one of the main limitations of their work was that the
PN graft had to be anastomosed to the severed optic nerve thus indicating how important
the proximity of the graft is to the damaged CNS region of interest. Meanwhile, there was
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little axonal growth into the nerve graft when the axons were injured a long distance away
from the perikarya.
Later, it was proposed that the gliosis at the interface between the nerve graft and
the CNS tissue can limit the ability of the CNS originated axons to expand beyond of the
graft (Bovolenta et al., 1993; Bovolenta and Fernaud-Espinosa, 2000). Yet, recent research
showed that the axonal regeneration could be further enhanced by modulating the
extracellular matrix in the CNS. For instance, applying chondroitinase to CNS lesions
before/after transplantation of SCs or PN tissue facilitated the regeneration of injured axons
and restored their functioning (Bradbury et al., 2002; Bradbury and Carter, 2011; Caggiano
et al., 2005, 2003; DePaul et al., 2015; Fouad et al., 2005; Houle et al., 2006; K R Jessen
and Mirsky, 2016; Liu et al., 2006).
Overall, observations from the use of different PN grafting techniques, which were
mainly pursued in the twentieth century (see Tables 1.1 and 1.2), concluded that: a) certain
CNS neurons can grow their axons at distances equivalent to the long tracts in rodents that
join widely separated areas of neuraxis (So and Aguayo, 1985); b) axons of some neurons
can potentially grow into a longer length after injury (Bray et al., 1987; Gage et al., 1985;
Villegas-Perez et al., 1988); c) many of the regenerating axons in the CNS arise from
injured neurons rather than sprouting from dormant ones (Friedman and Aguayo, 1985);
d) PN grafts stimulate central axons’ regeneration and significantly enhance the functional
recovery and early survival of axotomized ganglion cells such as retinal ganglion cells
(Aguayo et al., 1984; van Horne et al., 1991; Villegas-Perez et al., 1988) and e) grafting
PN tissue near neuronal cell bodies upregulates the expression of regeneration-associated
genes (RAGs) such as Tα1-tubulin, GAP-43 and c-Jun (Kobayashi et al., 1997; Merzenich
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and Jenkins, 1993; Schaden et al., 1994; Tetzlaff et al., 1991), which support the extension
of regenerating axons into the CNS. The question then becomes, where does the capacity
of the PN to regenerate come from? Findings from a wide variety of studies support that
the unique repair cell properties of SCs are the key.

The Role of Schwann Cells in Neuronal Survival and Axonal Regeneration

SCs derive from the neural crest cells which initially differentiate into Schwann
cell precursor. Eventually, immature SCs mature into myelin-forming and non-myelin
(Remak) SCs (Frostick et al., 1998; Jessen et al., 2015; Jessen and Mirsky, 2005). In
addition to maintenance of the axonal sheath and myelin production, the myelin-forming
and Remak SCs play a crucial role in the Wallerian degeneration of PN (Figure 1.1). About
a week after an axonal injury, those SCs start to divide and form Bungner’s bands, which
accept newly regenerating sprouts from the proximal axonal stumps (Gomez-Sanchez et
al., 2017). In fact, these dividing SCs acquire a novel phenotype with new characteristics
in addition to regaining some traits from their undifferentiated precursor state (Figure 1.1).

i. SCs re-express the molecules that characterize immature SCs in developing nerves,
including L1 adhesion molecule, p75 neurotrophin receptor (p75NTR), and glial
fibrillary acidic protein (GFAP) their precursors before being turned into myelinating
cells (Chen and Rajewsky, 2007; Jessen et al., 2015; Jessen and Mirsky, 2008).
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ii. Acutely after a nerve injury, reprogrammed SCs downregulate myelinating genes and
their related-transcription factors like Egr2 (Krox20), myelin-associated glycoprotein
(MAG), and periaxin (Arthur-Farraj et al., 2012; Fazal et al., 2015).
iii. SCs secrete neurotrophic factors like nerve growth factor (NGF), brain-derived
neurotrophic factor (BDNF), neurotrophin-3 (NT-3), NT-4/5, ciliary neurotrophic
factors (CNTF), and glial-cell line derived neurotrophic factor (GDNF) (Chan et al.,
2004; Höke et al., 2003; Ma et al., 2011; Michailov et al., 2004; Taveggia et al., 2005).
However, it is worth noting that changes in these factors differ in timing and site of
nerve injury. The upregulation of the neurotrophic factors tends to be higher in the distal
portion of an injured nerve during the acute phase of the injury (Boyd and Gordon, 2003;
Chen et al., 2007). SCs also secrete cytokines to recruit macrophages and neutrophils
(Lindborg et al., 2017). Some of these cytokines, like LIF and IL-6, act directly on
neurons to promote survival. Later, the recruited macrophages act as a maintaining
source of vital cytokines as the macrophages are polarized by the SCs toward an
alternative, the M2 phenotype. This phenotype promotes axonal outgrowth by releasing
essential anti-inflammatory mediators like IL10, arginase-1, chitinase-like 3/YM1, and
mannose receptor C type 1/CD206 (Al-Darraji et al., 2018; Haydar et al., 2019; Kroner
et al., 2014).
iv. SCs release VEGF and other factors to promote vascularization (Barrette et al., 2008).
v. Together with macrophages, SCs clear the myelin that inhibits new axon regeneration
(Hirata and Kawabuchi, 2002).
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vi. SCs form regeneration columns which are known as bands of Büngner. These bands are
important in guiding the newly regenerating axons to their correct targets (Jessen et al.,
2015).

Signaling pathways and mechanisms involved in reprogramming SCs

The emergence of the SCs’ repair phenotype is controlled mainly by the
transcriptional factor c-Jun (K R Jessen and Mirsky, 2016). Activation of other
transcription factors like Sox2, Id4 and Pax3 is also essential in initiating the
reprogramming process, but what differentiates c-Jun from other transcriptional factors is
that it simultaneously downregulates myelinating genes and upregulates regenerationassociated genes (Parkinson et al., 2008).
How c-Jun is activated remains unclear but inhibiting the activity of SCs’ c-Jun
greatly reduces the regenerative capacity of injured PN. Normally, c-Jun is suppressed by
Krox-20 in myelinating SCs. However, upon nerve injury, c-Jun becomes activated in the
distal stump (Arthur-Farraj et al., 2012; Chen et al., 2002; Parkinson et al., 2008). Jessen
and Mirsky’s group in 2012 used a c-Jun knock out mouse model to study the role of c-Jun
in the trans-differentiation of SCs after PN injury. The nerves of c-Jun mutant mice
appeared like those of wild type mice before injury. However, after an injury, a comparison
of the distal nerve stumps of wild type and c-Jun knock out mice showed that a remarkable
number of genes involved in regeneration and trophic support, like BDNF, GDNF, Artn,
Shh, and GAP-43, failed to upregulate. On the other hand, myelin-related genes such as
Mpz, Mbp, and E-cadherin failed to downregulate after an injury in c-Jun mutant mice.
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Importantly, reactivation of c-Jun by adenovirus transfer upregulated BDNF and GDNF
expression and fully restored the number of axons after injury(Arthur-Farraj et al., 2012).
The c-Jun signaling pathway also affects neuronal cell adhesion processes. Injured
nerves, from c-Jun knockout mice, expressed reduced N-cadherin and p75NTR but
elevated levels of NCAM (Arthur-Farraj et al., 2012). In addition to N-cadherin and
NCAM, Neurofascin-155, TAG-1, and Gliomedin are other major cell adhesion
proteins that are expressed during the regeneration process. Additionally, other studies
reported that SCs produce extracellular matrix molecules (like Fibronectin, Collagen I and
IV, and Laminin) that facilitate and guide axonal growth in PN environment (Eshed et al.,
2005; Spiegel and Peles, 2006; Tait et al., 2000; Traka et al., 2002).
Despite the major role of c-Jun in inducing the repair cell phenotype of SCs, other
transcriptional factors can act independently of c-Jun. For instance, the function of Sox-2,
a regeneration associated protein, is not affected by knocking down c-Jun after a nerve
injury (Arthur-Farraj et al., 2017, 2012). Nevertheless, the key function of the repair SCs
phenotype in preventing the neuronal death relies heavily on the activation of cJun. Selectively mutating c-Jun in SCs reduces the number of DRG neurons by about 50
% after an injury to PN. Interestingly, the number of proliferating SCs in the c-Jun
knockout mice was comparable to that of the wild type animals thus demonstrating that the
lack of axon regeneration and the increased neuronal death in c-Jun knock outs was
dependent on the new SCs’ phenotype rather than simply their proliferation.
The complete chain of events leading to c-Jun activation after PN injury has yet to
be fully elucidated. The events below describe the set of signaling pathways that are
involved in c-Jun activation after injury. Signaling molecules in the MAPK pathway are
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activated intracellularly in response to an injury including Erk1/2, JNK, and p38. These are
important regulators of the AP-1 transcriptional complex of which c-Jun is a key
component (Harrisingh et al., 2004; Napoli et al., 2012, 2009; Yang et al., 2012).
Activation of the Raf / ERK pathway with and without a nerve injury initiates the repair
phenotype of the SCs and induces a robust inflammatory response. This response is
reversible when the Raf/ERK pathway is switched-off (K. R. Jessen and Mirsky, 2016).
Furthermore, switching into the migratory repair phenotype is crucial for SCs to
form the regenerative tracks that cross-bridge the wound site. Formation of a new
extracellular matrix is crucial for SCs to travel along the regenerative tracks. Ephrin B
expressed by the fibroblasts activates EphB2 receptor on SCs which then induces the
relocalization of N-cadherin to the SC surface through the Sox2 transcription factor (Jessen
et al., 2015; Parrinello et al., 2010). While the extracellular tissue that is bridging the wound
sites is initially not vascularized, it becomes hypoxic. The macrophages sense the ongoing
hypoxia and secrete VEGFA, that is vital to induce the vascularization of the bridge and
subsequent SC migration (for review see Cattin et al, 2016, Stierli S, Glia 2019). Formation
and maintenance of the regeneration tracks by repair SCs, bands of Büngner, is decisive
for guiding the regenerating axons back to the terminal SCs at the original targets while
providing the essential trophic factors to support the survival of the proximally injured
neurons.
The repair capacity of SCs is increasingly motivating the curiosity of researchers.
A better understanding of this repair phenotype and how it is activated may, in the future,
change our ability to treat injury or damage in the CNS for conditions such as
neurodegenerative diseases. A recent study published by Parkinson and his team
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investigated the role of the Hippo/YAP (Yes-associated protein) pathway in controlling the
repair capacity of SCs (Mindos et al., 2017). Using a sciatic nerve crush injury model in
mice, Merlin-null nerves had a severely impaired axonal regeneration and remyelinating
capacity. The failure of Merlin-null nerves to repair was mediated by activating YAP,
which is a major Hippo pathway effector. To better test the relationship between YAP and
c-Jun expression, rat SCs were infected with adenovirus expressing the YAP protein. YAP
was localized to the nucleus and was associated with a significant downregulation of c-Jun
(Mindos et al., 2017). On the other hand, removing YAP restores c-Jun levels, neurotrophin
expression, and the functional recovery of the nerve after an injury. Taken together, these
findings indicate that Merlin expression and YAP inhibition help in switching SCs into
their repair phenotype.
Finally, the complexity of the different layers involved in driving the repair
phenotype of SCs has yet to be fully investigated. The recent work published by ArthurFaraj et al. raised several questions regarding the role of the appropriate regulation of
epigenetics for a proper repair of injured nerves. For instance, c-Jun-null nerves expressed
significantly lower levels of miR-21a-5p and miR-34b than controls. In contrast, other
miRNAs (miR96-5p, miR-124-3p, miR-183-5p, and miR-204-5p) were significantly
overexpressed (Arthur-Farraj et al., 2017). What is the physiological importance of such
micro RNAs and others in the repair process? Only the recent advances in the epigentic
research and its methodologies will help answering such key questions.
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Pre-clinical and clinical studies

Next, we review the preclinical and clinical literature exploring the hypothesis that
grafting PN tissue into the CNS might be utilized as a therapeutic approach to helping
repair the CNS and, in part, slow down, halt, or reverse the progression of PD and other
neurodegenerative diseases by employing the “repair cell’ properties of SCs. Ultimately,
we ask: can we use the signaling properties of the SC to explore how to repair the CNS?

Use of SC implants in spinal cord repair research

Several groups have tried to implement the regenerative properties of SCs to repair
the spinal cord after an injury. In different animal models of spinal cord injury,
transplantation of SCs has demonstrated tissue preservation, axonal regeneration and
myelination in addition to functional recovery (Kanno et al., 2014; Pearse et al., 2004;
Takami et al., 2002). To enhance the viability of transplanted SCs and reduce the
astrogliosis in an injured spinal cord, different matrices have been used to suspend SCs
pre-transplantation like Matrigel, Puramatrix, and Alginic acid sodium hydrogel (Kanno et
al., 2015; Moradi et al., 2012). These matrices were composed of a variety of extracellular
matrix components including collagen type IV, heparin sulfate proteoglycans, and
entactins (Kanno et al., 2014; Pearse et al., 2007). Additionally, several transplantation
methods were investigated to augment SCs survival and axonal regeneration including cotransplanting bone marrow stem cells (BMSCs) with genetically engineering SCs that
produce different neurotrophic factors (Table 1.1). The migration of SCs within the host
spinal cord tissue and their integration with the propriospinal axons were further facilitated
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by adding chondroitinase ABC to SCs or PN grafts with or without acidic fibroblast growth
factors (Bradbury and Carter, 2011; DePaul et al., 2015; Kanno et al., 2014; Zhao and
Fawcett, 2013). Chondroitinase degrades the chondroitin sulfate proteoglycans, which is
secreted by the astrocytes and leads to the formation of the glial scar. Also, grafting SCs
with olfactory ensheathing cells after spinal cord contusion unduces axonal growth and the
functional outcome (Fouad et al., 2005; Pearse et al., 2007; Ramón-Cueto and Avila, 1998).
Furthermore, co-transplantation of SCs with neural stem cells and bone marrow
mesenchymal stem cells overexpressing trophic factors promotes neuronal differentiation,
neuroprotection and outgrowth of serotonergic fibers, and enhances locomotor recovery
(Oraee-Yazdani et al., 2016; Pourheydar et al., 2012; Yazdani et al., 2013).
The preclinical work by Bastidas et al. (2017) investigated the use of cultured
human SCs to repair an injured spinal cord. Xenografts of human SCs were transplanted
into the spinal cord of nude rats and demonstrated both safety and ability of the cells to
survive and support histological regeneration and functional recovery of the CNS (Bastidas
et al., 2017). To study the role of human SCs in treating demyelinating diseases like
multiple sclerosis, Kohama and colleagues implanted human SCs in a demyelinating rat
spinal cord. Five weeks after transplantation, the electrophysiological recordings and
immunohistochemistry analysis showed a prominent survival of the transplanted human
SCs and extensive myelination with an increase in average conduction velocity (Kohama
et al., 2001). Thus, SCs which are normally contained in PN, can survive transplantation
and promote neural repair in a model of demyelinating diseases.
Meanwhile, Saberi group has tested autologous SCs transplantation on 33 human
participants who had chronic spinal cord injury. In the six months before the
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transplantation, study participants did not show any clinical improvement. Three to four
million cultured SC’s were injected into the injury site of the spinal cord (Saberi et al.,
2008). After two years, MRI results showed no evidence of abnormal tissue or tumor
growth at the injection sites. Clinical assessments showed significant improvement in the
sensory light touch test but no improvement in the pinprick sensation test. Only subtle
motor improvements were reported in the cases where the spinal cord injury had occurred
within three years; however, there were no significant improvements in sexual, sphincteric,
or functional assessments (Saberi et al., 2011). The lack of a significant improvement after
the transplantation could be due to many reasons including the chronic changes that might
have occurred between the injury onset and the transplantation timing. A larger enrollment
of participants along with a longer follow-up period could help clarify the potential clinical
significance of the effects this cell-based intervention. On the other hand, additional
elements of PN tissue, namely the macrophages, neutrophils, fibroblasts and disintegrated
axonal cytoskeleton, are needed to support the function of SCs and allow appropriate repair
of injured or degenerating CNS cells.
The first clinical trial under FDA approval was an open-label, unblinded,
nonrandomized and non-placebo-controlled Phase I study that involved six subjects with
subacute spinal cord injury. The primary endpoints of the trial were to evaluate the safety
and feasibility of implanting cultured SCs intro an injured spinal cord. Autologous SCs
were cultured in vitro from sural nerve and injected into the lesioned spinal cord. One year
after grafting, there were no major surgical, medical, or neurological adverse events related
to the transplanted SCs (Anderson et al., 2017).
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Human experience with implantation of SCs in neurodegenerative diseases

Neurodegenerative diseases, such as Alzheimer’s and PD are complex, chronic
disorders with cognitive and motor symptoms that result from the progressive neuronal
loss within cortical and subcortical areas of the human brain. The current pharmacological
treatments act on symptoms without slowing or reversing the ongoing deterioration in
neurons and their function. Nevertheless, preclinical research shows that at earlier
pathological stages, the neurons retain some characteristics to recover if they get enriched
with optimal neurotrophic media, such as NGF, BDNF or GDNF (Quintino et al., 2019).
Different “repair” strategies have been proposed to treat or replace degenerating neurons
in the CNS, especially in PD. These therapeutic strategies include transplantation of fetal
ventral mesencephalic tissue (Bakay, 1993; Freed et al., 2011, 2001; Hallett et al., 2014;
J.H. et al., 2017; Kordower et al., 2000; Li et al., 2008; Olanow and Fahn, 2006), delivering
neurotrophic factors to degenerating areas of the CNS (Kordower et al., 2000; Lindahl et
al., 2017; Slevin et al., 2007; Sullivan and O’Keeffe, 2016; Whone et al., 2019), and
autologous PN grafting (van Horne et al., 2018, 2016). Previous and current clinical
attempts to restore neuronal loss by transplanting fetal ventral mesencephalic tissue have
faced serious ethical and technical challenges although a few subjects did show some
improvement. We would argue that because of the ability of SCs to support neuronal
recovery in PNS, we may gain further insight into neuroregeneration through examining
these experimental models of grafting SCs in the CNS. Unfortunately, great difficulties
have been encountered in standardizing different isolation and culture protocols of SCs.
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Neurotrophic Factors as Putative Therapies

Pilot studies that have investigated the delivery of neurotrophic factors like GDNF
(Hoffer et al. 1994, Gash et al. 1996, Gash et al. 2005, Grondin et al. 2002, Grondin et al.
2019), Neurturin (Reosenblad et al. 1999; Oiwa et al. 2002, Gasmi et al., 2007, Grondin
et al. 2008), cerebral dopaminergic neurotrophic factor (CDNF; Voutilainen et al. 2011,
Airavaara et al. 2012), or BDNF (Tsukahara et al. 1995, Yurek et al. 1996), have shown
considerable promise in promoting, restoring or protecting dopamine containing fibers and
neurons. These are the primary type of neuronal cells affected in PD and are affected in
rodent and nonhuman primate models of dopamine depletion. Furthermore, coadministration of GDNF with NT-4/5, has a synergistic effect on increasing dopaminergic
neuron survival and stimulating dopamine release in rat organotypic explants (Di Santo
and Widmer, 2018). Nevertheless, the use of neurotrophic factors in humans, either by
direct delivery of GDNF (Nutt et al. 2003, Gill et al. 2003, Patel et al. 2013, Slevin et al.
2005, Lang et al. 2006), platelet-derived growth factor (PDGF-BB, Paul et al. 2015) or
AAV delivery of Neurturin (Marks et al. 2008, Marks et al. 2010, Bartus et al. 2013,
Olanow et al. 2015), have shown limited clinical benefits while identifying practical
dilemmas concerning the specificity of the therapeutic target. In addition, manufacturing
and purification of biologics, such as growth factors, is expensive, complicated, and can
complicate their use. Penetration of the neurotrophic proteins into brain parenchyma was
so problematic that a need evolved for direct versus gene therapy-based approaches to CNS
delivery (Marks et al., 2015, 2010; Salvatore et al., 2006). Recently, to improve striatal
GDNF exposure and optimize the pharmacodynamics and pharmacokinetics of GDNF, a
research group conducted a randomized, placebo-controlled study of convection-enhanced
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delivery of GDNF (Whone et al. 2019). The drug was administered intermittently every 4
weeks for 40 weeks using an intra-putamenal and bilateral skull-mounted, multi-cannula
transcutaneous port device (Whone et al., 2019). The study failed to meet its primary
endpoints, but a subsequent analysis of the extended treatment (80 weeks) showed
significant differences in motor activity and quality of daily living. But if the trophic factor
hypothesis remains valid, one question becomes: is one growth factor enough to slow or
stop the degeneration and/or restore injured neurons in the nigrostriatal system?
SCs within the autologous nerve grafts may serve as an alternative and natural
delivery source of many “repair molecules” including neurotrophic factors After
experimental results (Watts et al., 1997) demonstrated no major functional improvement,
possibly in part because of sample size limitations (only 5 participants), this area of
research had been suspended for more than two decades. Nevertheless, that trial and a
recent, single-case transplantation (Tabakow et al., 2014) of repair SCs, in the form of PN
grafts in combination with olfactory ensheathing cells, were able to show safety of the
procedure and some indications of possible efficacy. This work has helped revitalize the
concept of potentially using PN grafts in repairing the CNS.

PN grafting in nonhuman primate models of neurodegenerative diseases

Preclinical and clinical attempts to restore the nigrostriatal dopaminergic pathway
using dopamine secreting cells located within adrenal medulla grafts and human fetal
mesencephalic tissue were carried out in the 1980’s to possibly treat PD. Autologous
adrenal medullary transplantation alone resulted in poor graft survival while the human
fetal grafts appeared to initially produce little clinical improvement (Bakay, 1993; Brundin
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and Björklund, 1987). However, co-grafting adrenal medullary tissue with an autologous
PN tissue was tested by Watts and his team in n-methyl-4-phenyl-1,2,3,6
tetrahydropyridine (MPTP)-treated parkinsonian monkeys (Date et al., 1990; Watts et al.,
1997, 1995). Two small cavities were created in the caudate nucleus of two monkeys. Each
cavity was implanted with an adrenal medulla-sural nerve co-graft. Dexamethasone and
nonsteroidal anti-inflammatory drugs were administered postoperatively. The grafted
monkeys demonstrated significant improvements in their parkinsonian motor scores 6
months after the surgery. These results were also supported by EMG traces with increased
peak velocity of movements after grafting. Their study was unblinded and lacked surgical
sham controls thereby limiting the scientific judgment of the effect of the graft versus the
surgery itself on the study outcomes. However, this research group was able to
histologically demonstrate prolonged survival of the adrenal medulla cells along with the
peripheral SCs for months after the grafting procedure. These results may reflect the
potential of the PN grafts in biodelivering adequate trophic support to enhance the survival
of adrenal medullary cells and possibly repair the damaged host neurons at earlier stages
of a neurodegenerative disease.

Clinical trials investigating the potential of PN cell / tissue-based grafts to repair the
CNS

The concept of tissue transplantation into the CNS has been explored as a therapy
for the treatment of multiple conditions, including PD (Freed et al., 2011), multiple
sclerosis (Stangel, 2004), Huntington’s disease (Bachoud-Lévi et al., 2006; Gaura et al.,
2004), and spinal cord injury (Levi et al., 2002; Saberi et al., 2011). The safety of
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implanting autologous PN grafts in combination with other tissues into the CNS is
supported by the results of investigations in both non-human primate models (Levi et al.,
2002) and in patients with PD (Watts et al., 1997). Following positive results in a study
examining the efficacy of intrastriatal co-grafts of autologous adrenal medulla and sural
nerve in a macaque model of PD (Watts et al., 1995), the research team placed similar cografts in the basal ganglia of five human subjects with advanced PD (Watts et al., 1997).
Segments of the 11th intercostal nerve were harvested and stereotactically placed, together
with autologous adrenal medullary tissue, into the caudate nucleus and, putamen. The
concept was that SCs from transected PN segments could produce NGF to enhance the
survivability of transplanted adrenal chromaffin cells and the recovery of the host
nigrostriatal system (Date et al., 1990). Overall, the human surgery was reported to result
in no major complications and was ultimately deemed both safe and successful. The twoyear follow-up showed a mild to moderate improvement in Unified Parkinson’s Disease
Rating Scale (UPDRS) motor scores; yet, the improvement was not statistically significant.
This could be explained by the small sample size and the chosen locations of the grafts.
The safety of transplantation into the basal ganglia has been demonstrated by
Mendez et al. by placing fetal cell suspensions bilaterally into the substantia nigra, as well
as the putamen, without any perioperative or long-term complications (Mendez et al.,
2002). Meanwhile in 2001, Timothy Vollmer and his team at Yale implanted autologous
SCs into lesions in the frontal lobe of the brains of patients with multiple sclerosis. While,
to our knowledge, the results were never published, reports from the funding agency state
the surgical procedure was safe, with no adverse effects from the transplantation (The
Myelin Project). Other studies in both humans and animals have also shown the safety of
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transplanting purified SCs into the brain or spinal cord (Anderson et al., 2017; Kohama et
al., 2001; Pizzorusso et al., 1994; Saberi et al., 2011, 2008). One of the key benefits of
implanting autologous SCs is that each patient could serve as his/her own donor, thus
minimizing the need for immunosuppression (Stangel, 2004).
Could it be that perhaps because of these unpromising clinical results, and the rising
trend in the use of single growth factors such as GDNF or Neurturin to restore
dopaminergic function in PD (Funakoshi et al., 1993; Gash et al., 1996; Kordower et al.,
2000; Slevin et al., 2007) the therapeutic benefits of PN grafts for treating CNS disorders
have been undervalued over the past two decades? In addition, an emerging understanding
of the PN repair process helped further incorporate this cell-based therapeutic into clinical
trials (see Tables 1.1 and 1.2).

Using regenerative PN implants in PD to alter disease progression

In 2013 our research group initiated the first clinical trial to investigate the
hypothesis of using autologous PN grafts as a source of SCs to deliver crucial repair
molecules to the degenerating dopaminergic neurons in the SN of patients with PD
undergoing deep brain stimulation (DBS) surgery (Figure 1.2) (van Horne et al., 2018,
2016). The goal of the trial was to determine the safety and feasibility of implanting PN
grafts at the time of DBS surgery. This was the first clinical study that investigated the use
of autologous PN grafting in conjunction with DBS, an FDA-approved adjunctive therapy
to treat the symptoms of PD. The participants were tested with the DBS system turned off
and medications removed to washout their effects. Eight participants (6 males and 2
females) were included in the study with the mean (± Standard Deviation) age of 63 ± 9
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years, and mean disease-duration of 10 ± 4 years. All the participants consented for DBS
surgery targeting the subthalamic nucleus (STN) and for sural nerve grafting to the
substantia nigra (a procedure we have termed DBS Plus). The surgeries were done in two
stages on two different days (van Horne et al., 2015) (Figure 1.2).
During the first stage, the sural nerve was exposed and transected. The initial injury
to the nerve was expected to stimulate the SCs to reprogram themselves into the “repair
cell” phenotype as described previously in this review. The second stage was done 3-5 days
later, during which DBS electrodes were inserted bilaterally followed by unilateral grafting
of distal sural nerve fascicles, approximately 5 segments each about 1 mm in length into
the SN, contralateral to the most affected side. The targeting of the DBS electrodes and the
graft target location were confirmed to be accurate by postoperative 1.5 T MRI.
Adverse events of the grafting were comparable to that of DBS surgery alone. The
postoperative follow-up at 12 months reflected safety and tolerability of the grafting
procedure (van Horne et al., 2018). Only one participant suffered from superficial cellulitis
at the sural nerve incision site and 3 participants reported numbness along the sural nerve
dermatome. MRI of the midbrain showed no abnormalities acutely or at 12 months after
the surgery. Motoric impairment was measured using the UPDRS Part III while
participants were off therapy at 12 months. The mean scores were, 25 ± 16 points at 12
months vs 33 ± 10 points at baseline. The UPDRS test is scaled from 0-108 points, 0 is not
affected and 108 being most affected). This pilot study was able to reflect the safety and
feasibility of transplanting autologous SCs within conditioned PN tissue into the human
brain. To further validate the safety and explore the efficacy of this therapeutic approach,
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we have optimized the sample size in our ongoing studies (clinicaltrials.gov, registration
no. NCT02369003).
Our current ongoing studies (NCT02369003) have included patients who receive
DBS electrodes to the internal segment of the Globus Pallidus (GPi), another target for
DBS. One benefit of this approach is that the location is remote enough from the SN that
the grafts can be readily visualized with MR imaging. In addition to MRIs, SPECT imaging
using the radioligand, Iofluopane I123 injection (DaTscan™) has been implemented to
evaluate dopamine neuronal function in participants pre- and post-implantation of the sural
nerve grafts
In our studies, transplanting repair SCs within PN autografts is being investigated
as a conceivable disease-modifying therapy in PD. With no known cures, disease
modification remains one of the greatest unmet medical needs in the treatment of
neurodegenerative diseases like PD (Kalia et al., 2015). We continue to investigate
questions regarding dosing and optimization of bilateral placements of the PN grafts to
help lay the foundation for a blinded Phase II trial to better determine the efficacy of the
combined DBS and cell-based intervention.
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Table 1. 1 Critical studies that investigated the use of peripheral nerve tissue components in treating trauma and spinal cord
injury.

Trauma & Spinal Cord Injury
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Research
Experimental Design
Group
(David &
PN graft alone
Aguayo, 1981)

Model

Results

Bridging model in
transected model of
SCI in rats

Regenerating axons were guided by the PN
graft from the medulla oblongata to the lower
cervical and upper thoracic spinal cord

(Xu, Guénard,
Kleitman,
Aebischer, &
Bunge, 1995)

Graft of SCs + BDNF + NT-3

Transection model
of SCI in rats

Neurotrophins infused with the graft enhanced
propriospinal axonal regeneration and
promoted axonal regeneration of specific
distant populations of brain stem neurons into
the grafts

(Ramón-Cueto Combined SC-filled guidance
& Avila, 1998) channels + OECs transplants

Transection model
of SCI in rats

Robust ingrowth of 5HT-positive axons across
SC graft–cord interfaces and promotion of
long-distance regeneration of descending
supraspinal and ascending propriospinal axons

(Levi et al.,
2002)

Transection model
of SCI in
Cynomolgus
monkeys

Regeneration of theproximal spinal axons into
the PN grafts; the grafts significantly enhanced
the regeneration of myelinated axons into the
region of the hemisected spinal cord

Intercostal nerve autografts +
fibrin glue containing aFGF

Table 1.1(Continued)
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(Takami et al.,
2002)

Co-graft of OE glia and cultured
SCs

Contusion model of
SCI in rats

At 12 weeks after injury, SC-containing grafts
expressed more intense staining for glial
fibrillary acidic protein and chondroitin sulfate
proteoglycan compared with OEC-only grafts.
Propriospinal and brainstem axons reaching 5–
6 mm beyond the grafted area. SC graft is more
effective
in
promoting
axonal
sparing/regeneration than an SC/OEC or OEC
graft in the moderately contused adult rat
thoracic spinal cord

(Pearse et al.,
2004)

Schwann cell grafts with
phosphodiesterase IV inhibitor
(Rolipram)

Contusion model of
SCI in rats

Inhibition of cAMP hydrolysis by the
phosphodiesterase IV inhibitor rolipram
promoted
significant
supraspinal
and
proprioceptive axon sparing and myelination

(Fouad et al.,
2005)

Graft of SCs/OECs +
Chondroitinase ABC

Transection model
of SCI in rats

(Pearse et al.,
2007)

Co-grafts of SCs cultured from
sciatic nerves + OEC

Contusion model of
SCI in rats

Increased numbers of both myelinated axons in
the SC bridge and serotonergic fibers that grew
through the bridge and into the caudal spinal
cord
At 9 weeks post-implantation, OEC grafts
showed improved survival when transplanted
with SCs; modest improvements in open-field
locomotion and hind paw positioning

Table 1.1(Continued)
Grafts of SCs transduced with
D15A neurotrophic factor

Contusion model of
SCI in rats

At 6 weeks post-transplantation, SCs survived,
myelinated 5-HT, DβH, and CGRP axons and
their lengths were up to 5-times longer within
the transduced grafts

(Vavrek,
Pearse, &
Fouad, 2007)

Grafting of SCs with prolonged
ChABC infusion

Contusion model of
SCI in rats

Regrowth of raphe-spinal fibers from the brain
stem areas (vestibular nuclei and reticular
formation) into the SC bridge

(Ma et al.,
2010)

Sural nerve transplants + aFGF

Transection model
of SCI in monkeys

Improvement in walking performance at 16
weeks after surgery

(Moradi et al.,
2012)

Xenografts of human fetal SCs
encapsulated in PuraMatrix
scaffold

Contusion model of
SCI in rats

At 8 weeks post-transplantation, grafted SCs
infiltrated the injury site, suggesting that
PuraMatrix may play an important role in the
repair after human fetal SC is transplanted with
SAPNS

(Pourheydar et
al., 2012)

BMSCs + SCs

Contusion model of
SCI in rats

At 8 weeks post-transplantation, SCs survived
around the injury site, co-transplanted animals
showed an improvement of functioning but
greater allodynia
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(Golden et al.,
2007)

Table 1.1(Continued)
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(Kanno,
Pearse,
Ozawa, Itoi, &
Bunge, 2015;
Kanno et al.,
2014)
(DePaul et al.,
2015)

Graft of SCs transduced with
D15A neurotrophic factor +
ChABC

Contusion model of
SCI in rats

Increase of axonal regeneration caudal to the
graft; increase of locomotor and sensory
function

Graft of PN + aFGF + ChABC

Transection model
of SCI in mice

(Bastidas et
al., 2017)

Xenografts of human SCs

Contusion model of
SCI in rats

Regeneration of serotonergic and tyrosine
hydroxylase-positive axons across the lesion;
cytometry analysis and external urethral
sphincter electromyograms showed improved
urinary bladder function; reduction in collagen
scaring
At 6 months post-transplantation, there was no
evidence of tumorigenicity with preservation of
the white matter as well as axon growth and
myelination

Clinical Trials
(Tadie et al.,
2002)

Surgical bypass using segments
of autologous sural nerve from
thoracic cord levels into the
lumbar ventral roots

Humans with chronic
SCI (N=1)

At 8 months after transplantation, partial return
of motor function in the paralyzed legs after
nerve autografts

(Saberi et al.,
2011; Saberi et
al., 2008)

Intramedullary graft of
autologous SCs cultured from
sural nerve

Humans with SCI for
≥6 months (N=33)

At two years follow up, no major adverse
events were reported, but statistical
improvement in sensory scores. The duration
of SCI had no significant influence on sensory
results. Significant motor changes were
observed in those with duration of SCI < 3years

Table 1.1(Continued)
Autologous SCs cultured from
sural nerve +
Neurorehabilitation

Humans with SCI
1wk-20 months after
injury (N=6)

At 5 years of follow-up, grafting procedure was
feasible, safe, with mild to moderate clinical
improvement on ASIA motor and sensory
index; Smaller volume of myelomalacia and
cystic degeneration after SCs transplantation.

(Amr et al.,
2014)

Combined sural nerve grafts +
chitosan-laminin scaffold +
BMSCs

Humans with chronic
SCI (N=14)

Mild to moderate motor and sensory
improvements in the lower limbs; regaining
sensation of bladder fullness in all but 3
patients

(Tabakow et
al., 2014)

Co-grafts of autologous sural
nerve + OEC

Humans with SCI
(N=1)

At 19 months post-transplantation, no adverse
effects observed; Functional regeneration of
both efferent and afferent long-distance fibers;
partial bridging of the spinal cord at the nerve
grafts; Neurophysiological restitution of the
integrity of the corticospinal tracts

Humans with chronic
SCI (N=6)

No evidence of tumor overgrowth observed in
MR imaging for a mean of three years after cell
transplantation; no serious adverse effects were
reported
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(Zhou et al.,
2012)

(Yazdani et al., Combined intrathecal injection
2013)
of autologous SCs + MSCs

Table 1.1(Continued)
(Anderson et al., 2017)

Intra-spinal
transplantation of
highly purified
autologous SCs

Humans with
subacute SCI (N=6)

At 1-year post-transplantation, no serious
adverse events related to the cell therapy were
reported. There was no evidence of additional
spinal cord damage, mass lesion, or syrinx
formation. In one patient, there was an
atrophy and focal tethering of the spinal cord

PN: Peripheral nerve, SCI: Spinal cord injury; BDNF: Brain derived neurotrophic factor; NT-3: Neurotrophin-3; 5-HT: 5hydroxytryptamine, aFGF: acidic fibroblasts growth factor; OEC: Olfactory ensheathing cells; DβH: dopamine-β-hydroxylase;
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CGRP: Calcitonin gene-related peptide; BMSCs; Bone marrow stromal cells; MSCs: Mesenchymal stem cells; SAPNS: self‐
assembling nanofiber scaffold; ChABC: Chondroitinase ABC; ASIA: American Spinal Injury Association score

Table 1. 2 Critical studies that investigated the use of peripheral nerve tissue components in treating demyelinating and
neurodegenerative diseases.
Demyelinating and Neurodegenerative Pathologies
Graft Design

Model

Results

(Aguayo et al.,
1984)

Combined PN grafts +
mesencephalic fetal
transplants

6-OHDA lesioned rat
model for Parkinson's
disease

Fetal mesencephalic neurons survived and extended long
axons for about 2 cm along PN grafts inserted into the
striatum

(Gage et al.,
1985)

Combined PN grafts +
mesencephalic fetal
transplants

6-OHDA lesioned rat
model for Parkinson's
disease

7/26 implanted rats showed 70% recovery of motor
deficits with amphetamine-induced rotational behavior.
DA neuron grafts survived in both behaviorally
compensated and uncompensated rats; Neurites extended
the entire length of the PN bridge

(Kordower,
Fiandaca,
Notter, Hansen,
& Gash, 1990)

Intrastriatal
implantation of minced
adrenal medulla
combined + minced
sural nerve or sural
nerve alone

MPTP-treated rhesus
monkeys

Monkeys receiving an implant of nerve only, exhibited
survival of SCs and enhanced survival of adrenal cell 3
months after implant surgery

(Date et al.,
1996; Date et
al., 1994)

Intrastriatal co-graft of
adrenal medulla +
mouse sciatic nerve

MPTP-treated mouse
model of dopamine
system depletion

Immunocytochemistry indicated that co-grafts into the
striatum significantly enhanced adrenal cell survival and
tyrosine hydroxylase-positive host cells with a large
number of cells extending neurites
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Research
Group

Table 1.2 (Continued)
(Collier and

Mesencephalic neurons

6-OHDA lesioned rat

Increase in density and area of reinnervation of the host

Springer, 1991)

+ PN co-grafted into

model for Parkinson's

striatum, with co-grafts clearly providing more extensive

the adjacent lateral

disease

reinnervation

ventricle
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(van Horne et

Combined DA neurons

6-OHDA rat model of

Co-grafted animals exhibited significantly better

al., 1991)

grafts and minced

Parkinson's disease

functional recovery than animals receiving only DA

sciatic nerve tissue

neuron grafts

(Watts et al.,

Combined autologous

MPTP-induced

Adrenal cell survival was good to excellent in the grafted

1997, 1995)

sural nerve + adrenal

Parkinsonian

striatum

medullary tissue

Monkeys

intrastriatal
(Kohama et al.,

Grafts of SCs cultured

X-irradiation

Remyelination throughout the lesion with improved

2001)

from human sural

/ethidium bromide

conduction velocity and action potentials conducted over

nerves

lesioned

a greater distance into the lesioned dorsal columns

demyelination in rats
(Date et al.,

Co-graft of adrenal

Humans with

No postoperative complications with gradual and

1995)

medulla and PN into

Parkinson's disease

significant amelioration of the parkinsonian symptoms

the bilateral caudate

(N=1)

starting 2 weeks and continued for 2 year after

nuclei

transplantation

Table 1.2 (Continued)
Clinical Trials

34

(Date et al.,
1995, 1996)

Cograft of adrenal
medulla and PN into
the bilateral caudate
nuclei

Humans with
Parkinson's disease
(N = 1)

No postoperative complications with gradual and
significant amelioration of the parkinsonian symptoms
starting 2 weeks and continued for 2 year after
transplantation

(Watts et al.,
1997)

Combined unilateral
intrastriatal adrenal
medulla plus
intercostal nerve
cografts into the right
striatum

Humans with
Parkinson's disease
(N=5)

At two-year follow up, no morbidity was encountered.
Motor test scores during the “off” state improved by 35%
compared to baseline mainly in the side contralateral to
the graft.

(Timothy
Vollmer et al,
2011)

Grafts of cultured
autologous SCs in
frontal lobe lesions

Humans with
Multiple Sclerosis
(N=3)

Reports from the funding agency state the surgical
procedure was safe, with no adverse effects from the
transplantation

(van Horne et
al., 2017; van
Horne et al.,
2018)

Combined DBS with
Humans with
autologous sural nerve Parkinson's disease
graft implanted into the (N=8)
unilateral substantia
nigra

Adverse event profiles were comparable to those of
standard DBS surgery; UPDRS III motor scores suggest
improvement at one year compared to baseline mainly on
the side contralateral to the graft

PN: Peripheral nerve graft; 6-OHDA: 6-hydroxydopamine; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; DA:
dopaminergic neurons; DBS: Deep Brain Stimulation; UPDRS III: Unified Parkinson Disease Rating Scale Part III.

Figure 1. 1 Reprogramming of Schwann cells into Repair Cells.
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After a nerve injury, distal SCs dedifferentiate, re-express precursor markers, alter their morphology, and migrate within
regenerating tracks (Büngner bands). These tracks guide the regenerating axons back to their correct targets. Ephrin B expressed
by the fibroblasts activates Eph receptor B2 on SCs to promote expression of cell junctions and extracellular matrix molecules.
SCs crosstalk with the macrophages and interact with the released cytokines to activate different inflammatory pathways. The
axonal debris and the myelin are cleared up by both the repair SCs and the macrophages to promote the regeneration of new
axons. Pro-myelinating genes are downregulated through the cross-inhibition of Krox-20, POU domain class 3 transcription
factor 1 (Pou3f1 or Oct-6), myelin protein zero (MPZ) and myelin basic protein (MBP) by c-Jun, Sox-2, Pax-3, Id2, and Egr1/3
transcription factors. Repair SCs release various neurotrophic factors including NGF, BDNF, NT-3, NT-4/5, CNTF, trkB, trkA,
GDNF, and Neuregulin. These factors induce neurite growth locally and are retrogradely transported towards the perikaryon to
upregulate anti-apoptotic pathways and to enhance the function of injured neurons.

Figure 1. 2 Overview of DBS Plus Trial.

Grafting of autologous peripheral nerve implants in the substantia nigra of a human subject
with Parkinson’s disease. During Stage I surgery, a conditioning injury is introduced to the
sensory sural nerve to activate the repair phenotype of the Schwann cells. The distal
segment of the conditioned sural nerve, which contains the repair Schwann cells, is
harvested after two weeks during the stage II surgery. The epineurium is removed, nerve
fascicles are stripped and sectioned into petite segments and loaded into a custom-made
graft cannula. The grafts are stereotactically deployed into the degenerating substantia
nigra.
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CHAPTER TWO: MATERIALS AND METHODS

Clinical Trial Design

DBS Plus trial was designed as an open-label, single-center, Phase I clinical trial
that aims to assess the safety and feasibility of grafting autologous peripheral nerve
implants into the substantia nigra of patients with PD who were undergoing DBS surgery.
The secondary outcome measure of this trial is the motor signs assessment after surgery in
comparison to the baseline. The time frame is 24 months for participants who received
single-unilateral implants, and 12 months for the group of participants who received double
dose of the implants to the unilateral substantia nigra. The trial was registered with the
ClinicalTrials. gov database (http://clinicaltrials.gov), and its registration number is
NCT02369003. The study was reviewed and approved by the University of Kentucky IRB
committee, and the informed consent was obtained from all participants.

Participants Selection and Eligibility Criteria

Participants who have met the criteria for DBS surgery had been selected, informed
about the study, and consented for the DBS Plus the cell implantation procedure. Male and
female participants who are 40 to 75 years show a positive response to Sinemet
(Carbidopa/Levodopa), capable of tolerating the surgical procedure, and can follow up with
their appointments were included in the study. Those who showed mild to moderate
neurocognitive scores were excluded from entering the trial. UPDRS III assessments, both
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OFF and ON-medications, were done before the surgery, i.e., baselines scores. Participants
who have any medical condition that would not make them a candidate for DBS of the
STN or GPi or unable to give informed consent were excluded from the trial enrollment.
Females who are pregnant, lactating, or of child-bearing potential and unwilling to use an
adequate birth control method during the trial were also excluded from the study.

PPMI Database for PD Control

The data used for the PD Control group were obtained from the Parkinson's
Progression Markers Initiative (PPMI) database (www.ppmi-info.org/data). PPMI is
funded by the Michael J. Fox Foundation for Parkinson's Research and other funding
partners (www.ppmi-info.org/fundingpartners). PPMI is a result of the collaboration of
research centers of multiple sites around the word and biotechnology companies to find a
biomarker of PD progression. Those centers have obtained approval from the local IRB
committees and acquired consent from the participants. All observational data were then
de-identified and shared on the PPMI database. The PPMI website details description of
the PPMI methods in addition to the acquisition and dispensation of the data. The PPMI
Data were downloaded in November 2019. The database included 2117 PD participants
with a total of 14861 visits and an average of 7 visits per participant over a period of 6
years. Our analysis was focused on three-time points: Baseline, 12 months from baseline,
and 24 months from baseline. We aimed at refining the PPMI-control PD group to match
the inclusion and exclusion criteria of the DBS-Plus trial with the baseline set at the time
point when the participants score for MDS-UPDRS III of 30 and above on his/her visit.
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Subsequently, 80 participants from the PPMI Control PD database have matched the
inclusion criteria and completed a 24-month visit after.

Deep Brain Stimulation Plus PN Implantation Surgery

Deep Brain Stimulation (DBS) is a standard treatment for movement disorders such
as Parkinson's disease, Essential Tremors, and Dystonia. Also, DBS was demonstrated to
be effective in treating Epilepsy, obsessive-compulsive disorder, depression, and other
neurocognitive disorders. By sending out electrical stimuli, DBS acts on several
mechanisms to excite or inhibit different neuronal networks and modulate their synaptic
transmission (Herrington, Cheng, & Eskandar, 2016). The downstream effects of electrical
stimulation mainly depend on the chosen brain targets. The most common deep brain
targets for treating PD are the subthalamic nucleus (STN), Globus Pallidus Internal (GPi),
and caudal zona incerta nucleus(cZi). Those targets are carefully chosen with a
multidisciplinary team of neurologists, neurophysiologists, psychologists, and a
neurosurgeon to guarantee delivery of the best out symptomatic relief with a minimum side
effect. Participants were evaluated before surgery using MRI. The trajectories and entry
points of the DBS electrodes were mapped using Brainlab software (IPlan 3.0 Stereotaxy).
The grafting trajectory was also mapped in parallel to that of the leads. The DBS surgery
was done in two stages (van Horne et al., 2018).
At stage I, the pulse generator was implanted, and lead extensions were projected
from the chest to the skull. Next, the patient ankle was repositioned for a standard sural
nerve biopsy incision. The sural nerve was exposed and transected about 10 cm between
the lateral malleolus and the posterior border of the ankle. A 1 cm nerve sample was taken,
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and two silk ties were secured distal to the transection for better identification of the nerve
during stage II surgery. The incision was then closed in layers. The second stage of the
DBS Plus was completed two weeks later. Coordinates of the targets and trajectories were
calculated based on a fusion of the participants' CT scan and susceptibility-weighted
images sequences of MRI for better and precise targeting. After implantation of the DBS
electrodes, electrodes contacts were tested for efficacy and side effects. Once testing is
completed, a second burr hole was drilled and a guide cannula (FHC Inc., 1.8-mm outer
diameter) was then placed to target the Substantia Nigra contralateral to the most affected
parkinsonian side of the patient. The previously transected sural nerve was prepared, and
the distal stump of the nerve was identified. A 2-cm segment was harvested and rinsed with
normal saline. The epineurium was delicately removed, and the fascicles were removed
and dissected into five small segments of approximately 1 mm length. The segments were
then loaded in the graft cannula, which was placed to target the SN (Figure 1.2). The graft
cannula was then removed, and the dura was covered with the Durepair matrix from
Medtronic. The bur hole was filled with HydroSet. This sequence of events was planned
carefully not to intervene with the regular DBS procedure.
The participants received MRI 24-48 hours post-operatively and a complete MDSUPDRS III assessment during their follow-ups. A total of 18 participants with idiopathic
PD have consented for a bilateral DBS surgery targeting the GPi plus a single unilateral
nerve implant targeted to the substantia nigra pars compacta. A total of 9 participants with
idiopathic PD have consented for a bilateral DBS surgery targeting the GPi plus a unilateral
yet double dose of the PN implant targeted to the substantia nigra pars compacta.
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Safety and Adverse Events Assessment

Human participants were evaluated for long-term postoperative adverse events
(AE). Clinical monitoring timepoints for this dissertation report includes perioperative time
points, the 2-year evaluation visits for single and unilateral implanted participants, and 1year evaluation visits for participants who received double-unilateral implants. Through
those time periods, AE was recorded from the clinical reporting, chart review, and specific
queries during the clinical visits (van Horne et al., 2018). Postoperative 1.5-T MRI was
used for evaluation 24-48 hours after the implantation surgery. AEs were classified into
those which are related to DBS insertion or activation, graft-related procedure, or not
related to both. AEs were also categorized in severity from mild to severe according to the
Medical Dictionary for Regulatory Activities, version 11.0.

Motor Assessment: MDS-Unified Parkinson's Disease Rating Scale Part III

Movement Disorder Society-Unified Parkinson's Disease Rating Scale (UPDRS)
Part III is a standard clinical scale used to evaluate and assess the PD motor signs. The PD
participants were examined and scaled by one of 3 neurologists who are specialized in
movement disorders. Assessments were done in two states. During the OFF-medication
State, participants were assessed and scored after being off Levodopa-Carbidopa or any
other PD medications for about 12 hours. Then, participants were allowed to take their
prescribed Levodopa-Carbidopa dose, and they were re-assessed 1-2 hours afterward (State
2: ON-medication score). All post-op assessments are done with DBS stimulation being
turned off in order to tease out the effect of the electrical stimulation on the PD signs. MDS-
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UPDRS Part III is made of 18 items. Each subscale has 0-4 ratings, where 0 = normal, 1 =
slight, 2 = mild, 3 = moderate, and 4 = severe.

Tissue Collection for translational studies

Experimental procedures, including handling and implanting human peripheral
tissue, were reviewed and approved by the IRB of the University of Kentucky. Sural nerve
fascicles were obtained from living adult participants with PD (aged 45-70 years). The
donors had no known diagnosis of peripheral nerve pathologies or neurological illness
other than PD. The sural nerve samples were collected in two stages: Stage I was followed
by Stage II two weeks later. The sural nerves were dissected, and the nerve fascicles were
collected on average 30 and 60 minutes after harvesting from stage I and stage II surgeries,
respectively. Human peripheral nerve fascicles were obtained from 6 human subjects
undergoing DBS-Plus surgery for Parkinson's disease for RNA sequencing studies. For the
Neuro-Avatar experiments, human peripheral nerve fascicles, collected from both stage I
and stage II surgeries, were obtained from 4 human subjects undergoing DBS-Plus. The
removed section of the nerve was then stripped of its epineurium using microsurgical
dissection in cold, sterile saline. Individual fascicles of nerve fibers were separated using
jeweler's forceps, and the perineurium was discarded. These fascicles were placed in
conical micro-centrifuge tubes, snap-frozen on dry ice, and stored at -80°C until they were
assayed using RNA sequencing technique. The nerve fascicles that were collected for the
in vivo experiments, Neuro-Avatar, the fascicles were collected in sterile conditions,
placed on ice, and transported immediately from the operation room to the laboratory for
implantation.
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RNA Extraction

RNA isolation was performed by homogenizing sural nerve fascicles in 1ml of TRI
Reagent Solution (ThermoFisher AM9738) using a Fisher Scientific Power Gen 35
homogenizer with a microtip homogenizing probe. The homogenized lysate was
transferred to a pre-pelleted 5Prime Phase Lock Gel – Heavy 2 mL tube (ThermoFisher
NC1093153) and incubated at room temperature for 5 minutes. 200µl of chloroform was
added, and the tube was shaken vigorously by hand for 15 seconds. Phase separation was
performed by microcentrifugation at 12,000 x g for 10 minutes. The RNA containing
aqueous phase was taken from the top of the Phase Lock Gel layer and transferred to a 1.7
mL microfuge tube. RNA was precipitated by adding 0.5 ml isopropyl alcohol, mixed by
repeated inversion, and incubated at room temperature for 10 minutes. RNA was pelleted
by microcentrifugation at 12,000 x g for 10 minutes at 4°C. The RNA pellet was washed
two times, with 80% ethanol using a 7,500 x g microcentrifugation for 5 minutes at 4°C to
pellet RNA between washes. RNA pellets were air-dried 5-10 minutes at room temperature
and resuspended in 25µl of nuclease-free water. RNA purity was assessed by
OD260/OD280 ratio calculation using a ThermoFisher NanoDrop 1000. RNA integrity
was assessed by Agilent Bioanalyzer 2100 using the Eukaryotic Total RNA Nano assay.

RNA sequencing

RNA-Seq was performed at a strand-specific 100 cycle paired-end resolution in an
Illumina HiSeq 2500 sequencing machine (Illumina, San Diego, CA). In a repeated
measure design, mRNA from the six individual samples were sequenced pre and post
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lesioning; thus, resulting in a total of 12 samples. The 12 samples were multiplexed in two
lanes of a flow-cell, resulting in between 25 and 34 million reads per sample. The read
quality was assessed using the FastQC software (Andrew S. 2010). On average, the per
sequence quality score measured in the Phred quality scale was above 30 for all the
samples. The reads were mapped to the human genome (GRCh38) using the STAR
software version 2.3.1z (Dobin et al., 2013). On average, 96.4% of the sequenced reads
mapped to the genome, resulting between 24.3 and 32.8 million mapped reads per sample,
of which, on average, 89% were uniquely mapped reads. Transcript abundance estimates
were calculated using HTSeq (version 0.6.1) (Anders

S et al. 2015). Expression

normalization and differential gene expression calculations were performed in edgeR
(release 2.14) (Robinson & Oshlack, 2010) to identify statistically significant differentially
expressed genes. A paired sample design was used in edgeR, which employs a negative
binomial generalized linear model (NB-GLM) for statistical calculations. The edgeR
package implements advanced empirical Bayes methods to estimate gene-specific
biological variation under minimal levels of biological replication. The RNA composition
in each sample was normalized in edgeR using the trimmed mean of M-values (TMM)
method. The significance p-values were adjusted for multiple hypotheses testing by the
Benjamini and Hochberg methods and as modified by Storey (Benjamini & Yekutieli,
2005) providing a false discovery rate “q-value” for each differentially-expressed gene.
Genes with an absolute fold difference ≥ 2 and q ≤ 0.05 were considered statistically
significant.
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RNA-seq Analysis

RNA-seq data were organized in a Microsoft Excel table for subsequent analyses.
These normalized read counts (counts per million- CPM) were used to calculate foldchange between the pre-lesion and post-lesion samples, and the Log base 2 of fold change
was used for further analysis. Correlation matrices between different differentially
expressed transcription factors, and the respective genes were generated in JMP Pro 14
software. AmiGO Gene Ontology (GO) annotations (http://www.geneontology.org/) for
pathways of interest were cross-referenced with significantly differentially expressed
genes, yielding a list of differentially expressed genes related to each GO annotation's
respective biological function. The GO annotations chosen to be visualized in heat maps
were selected based on their relevance to peripheral nerve repair.16 Statistical criteria of q
<= 0.05 and |FC|>= 2 were selected, yielding a total of 3,641 differentially expressed genes
included in this analysis. Heat maps of the qualifying genes were generated using JMP Pro
14 (SAS). When applicable, hierarchical clustering was performed using Ward's method in
JMP.

Animal Care

All animal procedures were approved by the IACUC of the University of Kentucky
and were performed in accordance with the NIH guidelines for the care and use of
laboratory animals. Twenty-three adult male athymic nude rats (weigh 100-450 g; Charles
River Laboratories, Chicago, IL) were housed in micro-isolated cages and kept in a sterile
room with a 12-hr light/dark cycle. Autoclaved food and water were available ad libitum.
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Cages and bedding were changed every three days. Clinical observations, as well as health
and mortality records, were noted.

Implantation of Human Peripheral Neve in Neuro-Avatar

Young (4-8 weeks old) athymic nude rats (NIH-Foxn1rnu) were anesthetized under
isoflurane and received implants of human nerve fascicles into the dorsal striatum. A total
of 16 animals received nerve grafts (8 of stage I and 8 of stage II nerve fascicles). Half of
each animal group was randomly selected for brain collection and histological analysis at
two weeks, while the other half were euthanized at 6-month post-implantation. One mm3
of human nerve fascicle was delivered over 4 minutes using a 23-gauge adjusted needle
with a personal style and directed at the following stereotaxic coordinate within the
striatum: AP: +1.0mm, ML: -3.0 mm, DV: -5.0 mm. After implant deployment, a 4-minute
wait period was maintained to allow attachment of the implant to the host brain tissue, the
skin wound was stapled, and the animal was allowed to recover from anesthesia.

Histological Procedures

At the endpoints (two weeks and six months) post-transplantation, animals were
deeply anesthetized using a single dose of pentobarbital (100 mg/kg IP) and transcardially
perfused with 250 mL of normal cold saline followed by 180 mL of 4% Paraformaldehyde
(PFA). The brain was extracted and postfixed with 4% PFA for at least 24 hours. Following
post-fixation, the implantation site was identified and cut into a 1 cm section in brain mold
and cryoprotected in 30% sucrose for three days. Cryopreserved brains were cut coronally
into 40 µm thick sections for staining.
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Immunostaining

To identify the transplanted human peripheral nerve cells and examine their
interaction with the host CNS, immunostaining with antibodies against Human Nuclear
Antigen (HNA) was employed. Tissue series from the grafted brain sections were subjected
to the Anti-HNA antibody together with DAPI (4′,6-diamidino-2-phenylindole). The
primary antibody used was Mouse Anti-human HNA (1:500; Catalog#: ab191181, Abcam,
Cambridge, MA). The fluorescent secondary antibody was Alexa conjugated goat Antimouse IgG (1:500; Catalog#: ab150113, Abcam, Cambridge, MA). To ensure the
specificity of observed immunostaining, both positive and negative controls were included
during staining. Negative controls consisted of the incubation of the primary or secondary
antibodies alone, in addition to a non-grafted and intact rodent brain collected after six
months of the experiment. Positive Controls consisted of incubation of sections of human
sural nerve collected during both stage I and stage II surgeries. The brain sections were
transferred from their wells and washed once with PBS. The tissue was permeabilized
using 0.2% Triton X-100 for 5 minutes and then washed with PBS once. The slides were
blocked with 5% goat serum, 1%Triton X-100 for 1 hour. Afterward, the slides were
incubated with the primary antibody in PBS, 0.1% goat serum overnight at 4'C. The next
day, the slides were washed with PBS, 3x5 minutes, and incubated with fluorescenceconjugated secondary antibody in PBS, 0.1% normal serum for 1-2 hours at RT in the dark.
Finally, the slides were rinsed in PBS, mounted on coverslips, and examined under a
fluorescent microscope.
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Magnetic Resonance Spectroscopy

Magnetic Resonance Spectroscopy is possible on any nucleus producing a magnetic
moment. The metabolically active proton nuclei (1H) is the most sensitive for NMR, and
it allows us to detect a large number of important amino acids and metabolic pathways' end
products like N-acetyl aspartate (NAA) and Creatine (Cr) /phosphocreatine. In healthy
brain tissue, the most prevalent resonance originates from the methyl group of NAA at 2.02
ppm (Moffett et al., 2007). The chemical shifts are referenced in regards to that of 3(trimethylsilyl)1-propane sulfonic acid at 0.00 ppm. NAA is exclusively localized in the
CNS as well as the PNS. NAA has been used as a marker for viable neurons as it is only
found in neurons, and its concentration decreases in the neurodegenerative diseases which
affect the CNS (Schuff et al., 2006). The NAA concentration is yet not uniform and varies
between gray matter (8-11 mM) and white matter (6-9 mM) (Moffett, Arun, Ariyannur, &
Namboodiri, 2013; Moffett & Namboodiri, 1995). The methyl and methylene protons of
creatine and phosphocreatine resonate at 3.03 ppm and 3.93 ppm. Since the sum of both
forms, total creatine (tCr), is constant in adulthood, the later can be used as a suitable in
vivo concentration reference. Glutamate and Glutamine peaks were determined at 2.1-2.5
ppm and 3.7 ppm, respectively. Brain morphology and metabolism were assessed using
T2WI magnetic resonance and imaging MRI and MRS (7-tesla Horizontal bore magnet;
Bruker/Siemens scanner) at three months post-implantation in Neuro-Avatar animals. Two
animals were used for MRS studies at three months post-implantation. The first one was a
neuro-avatar athymic rat that has received a stage II human nerve implants into the right
dorsal striatum. The second animal was a sham animal where a cannula with PBS, and no
nerve implant was inserted into its striatum. Rats were deeply anesthetized by 2%
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isoflurane. The heads of the rats were fixed in a body retainer, the respiratory rate was
monitored, and the body temperature was maintained at 37 oC with a body heating pad.
The spectra were acquired at TR/TE/NS=2500/3/200 for ipsilateral as well as the
contralateral striatum with the voxel (volume = 3×2×3 mm3) placed just next to the graft
trajectory. Ipsilateral metabolic concentrations were normalized to the contralateral (intact)
ones before comparing the two treatment groups.

Thesis Outline

The following chapters investigate the use of peripheral nerve implants in
combination with DBS to alter the disease progression of PD. Peripheral nerves have a
remarkable potential for repair and regeneration in response to an injury compared to the
CNS (Gu et al. 2014, Sheng Yi et al., 2018). Schwann cells, within the distal stump of the
injured nerve, play a major role in promoting and maintaining axons regeneration from the
proximal stump. Those cells release neurotrophic factors and cross-talk with the basal
lamina, fibroblasts, and immune cells to ensure adequate regeneration. In our first study,
we analyzed, using high throughput RNAseq analysis, the impact of the conditioning
transectional injury on human sural nerve's molecular pathways at 14 days following the
injury. Our main goal was to validate if the nerve implants collected from participants with
PD will contain the repair molecules that are required to induce neuroprotection and axons
regeneration of the degenerating nigrostriatal system.
In Chapter Four, we studied the viability and trophic effect of the nerve implants
after being implanted in the CNS. Pre-lesion and post-lesion sural nerve implants were
collected from participants undergoing DBS Plus and implanted into the dorsal striatum of
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athymic and immunodeficient rats. Immunostaining for human Schwann cells at six
months post-implantation (longest period examined) demonstrated the ability of those cells
to tolerate the grafting procedure and to survive the central nervous environment.
Furthermore, stage II (14 days post-lesioning) nerve implants contained a higher load of
cells and were able to survive better up to 6 months post-implantation when compared to
Stage I (pre-lesion) nerve implants. Additionally, the brain tissue reaction to the human
nerve implants was evaluated using in vivo magnetic resonance spectroscopy
In Chapter Five, we examined the safety and efficacy of combining DBS surgery
with autologous nerve implant stereotactically targeted to the substantia nigra of human
subjects with PD. In this study, two treatment groups of participants were studied. The first
is a group of 16 human subjects who received a single and unilateral dose of nerve implant
while in the second group, nine human subjects with PD have received a double-unilateral
dose of nerve implants. The participants were followed up to 24 months after the surgery.
The adverse events reported by both study groups were similar to those of DBS surgery.
On the other hand, the clinical motor assessments indicated an improvement in UPDRS III
scores up to two-years after-grafting. The post-hoc analysis demonstrated that the
improvement in the parkinsonian signs was mostly lateralized to the side contralateral to
the implanted substantia nigra. Finally, we discuss how the combination of Deep Brain
Stimulation Surgery and autologous peripheral nerve implantation could be a safe and
promising intervention to alter the disease progression in Parkinson's disease.
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CHAPTER THREE: TRANSCRIPTOME ANALYSIS OF IN VIVO
PREDEGENERATED PERIPHERAL NERVE

Abstract

The development of regenerative therapies for central nervous system diseases can
likely benefit from an understanding of the peripheral nervous system repair process,
particularly in identifying potential gene pathways involved in human nerve repair. This
study employed RNA sequencing technology (RNA-seq) to analyze the whole
transcriptome profile of the human peripheral nerve in response to an injury. The distal
sural nerve was exposed, wholly transected, and a 1-2 cm section of nerve fascicles were
collected for RNA-seq from six participants with Parkinson’s disease, ranging in age
between 53 and 70 years old. Two weeks after the initial injury, another section of the
nerve fascicles of the distal and pre-degenerated stump of the nerve were dissected and
processed for RNA-seq studies. An initial analysis between the pre-lesion status and the
post-injury gene expression revealed 3,641 genes that were significantly differentially
expressed. Our results provide evidence for the trans-differentiation process that occurred
by the end of the 2-weeks post-injury. Gene ontology and hierarchical clustering were used
to identify the major signaling pathways affected by the injury. In contrast to previous nonclinical studies, substantial changes were observed in molecular pathways related to glial
cell proliferation, neurotrophic factors release, Axonogenesis, neural synaptic plasticity,
and PD-causative genes. The results of our current study provide new insights regarding

51

the essential interactions of different molecular pathways that drive neuronal repair and
axonal regeneration in humans.

Introduction

Peripheral nerves have a spectacular capacity for regeneration in comparison to the
CNS (Scheib & Höke, 2013). Regardless of the type of the injury, the distal stump of the
peripheral nerve initiates an orchestrated pattern of complex cellular and molecular events
leading to proximal neuron survival and axon regeneration towards the original target. This
series of events, which have been known as Wallerian degeneration, take place over mainly
two stages (K. Jessen & Mirsky, 2016). The early-stage happens within the first five days,
and the later stage occurs 1-2 weeks after injury. During the early stage, the axonal debris
and myelin are cleared by SCs and the invading immune cells followed by morphological
changes of the SCs to facilitate their migration and formation of the regenerative tracks
(Bands of Büngner). Promotion of the Axonogenesis and neuronal repair occurs mainly
during the later stage. This regenerative capacity of the peripheral nerve highly depends on
genetic changes driving adequate SCs-axon interaction, appropriate immune cells’
response, and suitable release of neurokines, chemokines, and growth factors. Trophic
factors such as GDNF, NGF, the FGFs, neurotrophin-3 (NT-3), BDNF, PDGF, interleukin1, and apolipoprotein E, facilitate SC and neuronal survival, axonal elongation as well as
an anti-inflammatory response for (review see (Li et al., 2020)). Moreover, the adequate
delivery of cytokines, including tumor necrosis factor α (TNFα), tumor growth factor β
(TGFβ) and leukemia inhibitory factor (LIF) is essential to avert exaggerated inflammatory
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cascades and production of chondroitin sulfate proteoglycans (CSPGs) which can impede
neuronal survival and axonal outgrowth (K. Jessen & Mirsky, 2016).
Identification of the genes involved in peripheral nerve regeneration and how they
interact is crucial to exploring strategies that enhance the neural protection, regeneration,
and repair processes. On the other hand, promoting successful regeneration in CNS has
been difficult in neurodegenerative diseases, traumatic brain injury, stroke, epilepsy, and
PD. Yet, understanding the gene expression changes that drive effective neural repair
within the PNS may also help in identifying new therapeutic targets or methods that could
enhance CNS neural regeneration.
Whole-transcriptome profiling of gene expression in response to peripheral nerve
injury can now be feasibly studied using RNA sequencing (RNA-seq) technology. RNAseq combines molecular biology approaches of RNA amplification with bioinformatics
tools for measuring and validating large RNA sequencing datasets. This technique allows
for quantitative measurements of thousands of gene transcripts using small (10-30 mg or
less) quantities of tissue (for reviewing the applications of RNA-seq see (Han, Vickers,
Samuels, & Guo, 2015)). The study reported herein presents the analysis of the
transcriptome profile of in vivo predegenerated sural nerve tissue in patients with PD and
to help evaluate how a conditioning injury of peripheral nerve tissue can induce proregenerative changes.
Our study was conducted in conjunction with an ongoing clinical trial
(clinicaltrials.gov:NCT#02369003;https://clinicaltrials.gov/ct2/show/NCT02369003?term
=NCT02369003&cond=Parkinson+Disease&draw=2&rank=1), the “DBS Plus” trial,
which involves grafting of autologous peripheral nerve fascicles in patients with
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Parkinson’s disease (PD) at the time of deep brain stimulation (DBS) surgery. To our
knowledge, this study is the first of its type studying and analyzing the human peripheral
nerve genetics in response to a transection injury within the same human subjects. The trial
involved a collection of two samples of the sural nerve from the same participants at two
distinct time points. The first sample, referred to as the “pre-lesion” sample, was collected
from the participant’s sural nerve during Stage I of the surgery, which involved DBS
hardware implantation. The second sample, referred to as the “post-lesion” sample, was
taken two weeks later from the distal end of the same nerve during Stage II of the surgery,
which is the stage when the DBS leads are positioned into the STN or GPi nuclei. This
two-stage approach corresponded with the two stages of DBS surgery and was designed to
induce pro-regenerative changes in the peripheral nerve following an injury (van Horne et
al., 2017).
In our current study, we hypothesize that pre-conditioned implants harvested from
the distal stump of the sural nerve in participants undergoing the stage II of DBS Plus, 14
days post-lesioning, will hold a transcriptional profile that promotes nerve regeneration
during the later stage of Wallerian degeneration.

Research Subjects

The nerve samples were collected from human participants with PD who electively
participated in the clinical trial testing the safety and feasibility of peripheral nerve implants
to the CNS for the treatment of PD. The nerves samples of 6 participants, (two females,
four males) aged 63.8 + 6.9 SD years (range 53-70 years), were used for RNA-seq analysis.
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The study was approved by the University of Kentucky institutional review board, and
informed consent was obtained from all study participants.

RNA Collection and Sequencing

RNA collection and sequencing were done as described in the Methods section of
Chapter Two. In a repeated measure design, mRNA from the six individual samples were
sequenced pre and post lesioning; thus, resulting in a total of 12 samples. These normalized
read counts (counts per million- CPM) were used to calculate fold-change between the prelesion and post-lesion samples, and the log base 2 of fold change (log2FC) was used for
further analysis. Genes with an absolute fold difference ≥ 2 and q ≤ 0.05 were considered
statistically significant, yielding a total of 3,641 differentially expressed genes included in
this analysis. AmiGO Gene Ontology (GO) annotations (http://www.geneontology.org/)
for terms of interest were cross-referenced with significantly differentially expressed
genes, yielding a list of differentially expressed genes related to each GO annotation’s
respective biological function. Heat maps of the qualifying genes were generated using
JMP Pro 14. Hierarchical clustering was performed using Ward’s method in JMP.

Results

Nerve Tissue Collection

The mass and freezing delay time (time from when the nerve was harvested from
the participant to when it was snap-frozen in dry ice) were calculated for the nerve tissue
collected for RNAseq from Stage I and Stage II (Table 3.1). Freezing Time Delay was
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significantly longer (p-value= 0.0022, Figure 3) at Stage II (two weeks after injury) (59 ±
25 min; Mean ± SD) compared to Stage I (Intact state) (18 ± 5 min). This difference was
a result of the longer technical surgical procedures needed for the clinical trial during
Stage II of the DBS surgery. The mitigation of Mass Effect during the RNA Access
library prep is accomplished in multiple ways through normalizations incorporated at
multiple steps through the entire process of library prep and sequencing.

Glial Cell Proliferation

Figure 3.2 shows all significantly differentially expressed gene transcripts
annotated with the GO term “Positive Regulation of Glial Cell Proliferation”
(GO:0060252) in Homosapiens. Out of 19 unique genes with this GO annotation, 6 of those
genes (IL1B, LYN, E2F1, PRKCH, MYB, IL6) were significantly differentially expressed
while only one gene (PLAG1) appeared to be less expressed 14 days after the initial nerve
transection injury. On the other hand, 7 genes (IDH2, CERS2, SOX10, DICER1, PTN,
HES1, ADCYAP1R1) out of 16 genes associated with “Negative regulation of glial cell
proliferation” (GO:0060253) were differentially significantly expressed.

Growth Factor Activity

Figure 3.3 shows all significantly differentially expressed (q< 0.05, |FC|>2) gene
transcripts annotated with the Gene Ontology (GO) term “Growth Factor Activity”
(GO:0008083). Out of 166 unique genes with this GO annotation, 43 (25.9%) were
significantly differentially expressed two weeks after the initial injury (collected during
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Stage II). Twenty-six of those genes were enriched in the predegenerated nerve tissue in
comparison to normal levels while 17 genes were less abundant

Regulation of Axons Regeneration and Extension

Out of 96 genes associated with gene ontologies: “Regulation of Axon Extension”(GO: 0050772) and “Axon Regeneration” (GO: 0045773), 12 genes were significantly
upregulated in the distal nerve tissue after injury in comparison to their initial transcript
levels which were sequenced and measured in the sural neve samples collected during stage
I surgery (Figure 3.4). The expressed genes included PLXNC1, SCARF1, HGF, BDNF,
NRP1, FKBP1A, GRN, LIMK1, FN1, HCLS1, TRPV2, and TNFRSF12A. On the other
hand, 12 genes were transcribed at significantly lower levels two weeks after the initial
conditioning injury to the sural nerve during stage I surgery.

Regulation of Neural Synaptic Plasticity

All five human genes associated with the gene ontology term “Positive Regulation
of Neural Synaptic Plasticity” (GO:0048170) demonstrated higher transcript levels in the
distal nerve tissue harvested during stage II surgery in comparison to that from stage I
surgery (Figure 3.5). Of particular interest, SHANK3 and KIT genes were significantly
expressed with FCs levels of 2.44 (p-value = 2.56183E-12) and 2.14 (p-value = 7.16588E07) respectively.

57

Associated Transcription Regulatory Factors

624 unique transcription factors (TFs) with regulatory functions related to the 26
growth activity-associated genes, which were significantly upregulated (figure 3.2), were
identified based on the Genecards database (a repository of a database for human gene and
proteins with links to other databases https://www.genecards.org/). 267 TFs were
differentially and significantly between stage I and Stage II with p or q values ≤ 0.05 and
|FC| ≥ 2. Yet, only 38 TFs (figure 3.3) were differentially expressed and with an expression
profile that is significantly correlated (|Pearson correlation| ≥ 0.8) to the expression trends
of the growth factors. The correlation matrixes were calculated and plotted by JMP Pro14
software. Out of the total 38 TFs, 31 TFs were significantly expressed and had a strong
positive correlation of expression with at least one of 21 Growth factors. On the other hand,
22 TFs were significantly downregulated after injury, while their expression profile had a
significant and strong negative correlation with at least one out of 18 Growth factors (figure
3.6). Of particular interest was the downregulation of AHR transcription factor (FC= 2.023) while its downregulation was significantly correlated to the upregulation of GDNF
(FC=3.54, Correlation = -0.98, and p-value = 0.0006).

Transcriptome Profile of PD-Related Genes

Mutations in more than 20 genes have been identified and linked to Parkinson’s
disease. The hallmark pathology of PD is the deposition of Lewy bodies within the
dopaminergic neurons. Lewy bodies are protein aggregates consisting of different proteins,
including α-synuclein (encoded by the SNCA gene). PD is one of the most common
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synucleinopathies; other synucleinopathies include multiple system atrophy and Lewy
body dementia, which clinically overlap with PD (Cornelis Blauwendraat et al. , 2020). We
were interested in studying the expression of SNCA and other PD-related genes in the
peripheral nervous system of patients with PD and how their transcriptomic profile would
change in response to an injury. Differential expression analysis of RNA transcripts-count
per million (CPM) values using p < 0.05, FDR < 0.05, and |Log2FC| ≥ 1 as cutoff criteria
produced a total of 8 transcripts differentially expressed between intact nerve tissue (stage
I) and post-injury profile (stage II). Among these differentially expressed genes, seven
transcripts (SNCA, LRRK2, PLA2G6, DNAJC6, MAPT, SIPA1L2, and PDZRN4) were
downregulated and only one (GCH1) was upregulated two weeks after nerve injury (figure
3.7a, 3.7b). Of particular note, SNCA gene transcript was significantly downregulated
(Log2FC = -2.5, p-value=1.5E-18, FDR=2.49E-17).
To further study the molecular signaling that might have played a role in the
downregulation of those PD-related genes, we identified through the Reactome database a
total of 103 candidate transcription factors (TFs). Those TFs were either directly or
indirectly correlated to the signaling pathways involved in the expression of PD-related
genes. Only 25% of those TFs were differentially expressed after injury, and their
transcriptomic profiles were significantly correlated to the expression of the PD-related
genes with a cutoff threshold of |Pearson’s correlation| ≥ 0.8, and p-value < 0.05 (figure
3.8). 7 TFs (SMARCA4, TFDP1, XRCC5, ZNF792, MAZ, SOX13, and DRAP1) were
identified as potential repressors of 5 PD-related genes (SNCA, MCC1, LRRK2,
PARK2, and DNAJC6). The expressions of those TFs were upregulated and significantly
correlated to the downregulation of PD genes’ expression. Two noteworthy potential
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repressors for SNCA gene expression were identified: ZNF792 and DRAP1. On the other
hand, 17 potential enhancers were identified and positively correlated to the expression of
7 PD-related genes (SNCA, LRRK2, PDZRN4, DNAJC6, MCCC1, PARK2, and PINK1).

Discussion

In this study, we present the relevant transcriptome of human sural nerve tissue and
characterize transcriptional changes at 14 days following a transectional injury. We provide
evidence that the transection lesion paradigm used in the DBS Plus surgeries induces
phenotypic changes in the peripheral nerve tissue consistent with the peripheral nerve
repair response: immune cell infiltration plus cell proliferation, Wallerian degeneration of
axons, and up-regulation of growth factors production (Arthur-Farraj et al., 2012; ArthurFarraj et al., 2017; Cattin & Lloyd, 2016; K. R. Jessen & Arthur‐Farraj, 2019). Our
experimental design included harvesting sural nerve tissue from 6 human subjects who
were undergoing DBS surgery for PD. The mRNA from a total of 12 individual samples
were sequenced and measured pre and post lesioning using RNA Sequencing technique.
Normalized read counts (CPM) were used to calculate fold-change between the pre-lesion
and post-lesion samples, and Log2FC was used for further analysis. Genes with an absolute
fold difference ≥ 2, p ≤ 0.05, and FDR ≤ 0.05 were considered statistically significant,
yielding a total of 3,641 differentially expressed genes. AmiGO Gene Ontology (GO)
annotations for specific signaling pathways were cross-referenced with significantly
differentially expressed genes, yielding a list of differentially expressed genes related to
each GO annotation’s respective biological function.
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A large number of differentially expressed genes were identified, most of which
were involved in growth factor activity, glial cell proliferation, axon regeneration and
extension, and positive regulation of neural synaptic plasticity, based on Gene Ontology.
To better refine the results of our RNA-seq analysis to a more “biologically relevant”
dataset, we decided to limit our observations to the genes whose transcript levels exceeded
a fold change threshold of |FC|>2. However, this convention might have excluded genes
that were biologically relevant at lower fold changes. For example, the transcription of NF2
gene, a marker of Schwann Cell proliferation, was statistically significantly increased (pvalue =0.0192). However, the fold change of transcript levels was less than 2, so it was not
included in the visualized data. Likewise, Mesencephalic Astrocyte Derived Neurotrophic
Factor (MANF) transcripts level was significantly higher post-injury (p-value= 3.03E-07),
yet its FC was 1.754 (data not shown). MANF plays a vital role in different reparative
phases during the neuronal regeneration processes, and MANF therapeutics are expected
to enter clinical trials (Sousa-Victor, Jasper, & Neves, 2018). Furthermore, we focused in
this paper only on transcripts that were differentially expressed between pre- and postlesion samples while recognizing that some genes could be highly expressed in both stages,
but not necessarily differentially. That could be one limitation of this broad analysis
approach, and in the specific case of NF2 levels in this tissue merits further study.
The gene cluster of the growth factor terms showed multiple differentially
expressed genes, with the majority being increased. One increased gene of note is GDNF,
which is neuroprotective and neurorestorative of dopaminergic neurons and has been tried
as a therapeutic intervention for PD in preclinical and clinical studies (Quintino et al., 2019;
Slevin et al., 2007; Whone et al., 2019). All post-lesion nerve samples, except one,
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demonstrated an upregulation of GDNF transcription. Only the nerve sample collected
from participant number 2 showed a lower number of GDNF transcripts after injury (Figure
3.3). The significant longer freezing time delay for this sample (Table 1) might have
negatively affected GDNF-mRNA stability and its relevant count during RNAseq
processing. Multiple interleukins were also upregulated, which, in addition to being
cytokines, play a role in neurogenesis (Borsini, Zunszain, Thuret, & Pariante, 2015).For
example, the levels of gene transcript for IL-6, which has been described as neuroprotective
against focal brain injury, were increased in response to the nerve injury (Penkowa et al.,
2003). The growth factor activity genes, which were decreased (for example, CDNF) at
two weeks post-injury, are also of interest and may indicate the complexity of the neuronal
repair process in regard to the changes of individual growth factors over time in response
to nerve injury. That was evident in the work of Lin et al., 2019 as PPAR, PI3K-Akt, and
chemokine signaling pathways were dominant in early Wallerian degeneration (Lin, Xie,
Zhou, Yin, & Lin, 2019). Whereas at the later stage, the main signaling pathways were
ErbB, tumor necrosis factor, AMPK, MAPK, PPAR, and Wnt.
To our knowledge, this is the first report to publish data about the transcriptional
regulators and the enriched growth factors after human peripheral nerve injury. Over 600
transcription factors potentially related to the expression of upregulated growth factors
were generated through Reactome libraries (http://www.reactome.org/). Only 38
transcription regulators were differentially expressed and significantly correlated in the
upregulation of 24 growth factors, which were upregulated (figure 3.6). These findings
substantially add to our understanding of the signaling pathways which intervene in
enhancing or repressing the synthesis of several essential growth factors. For example, the
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aryl hydrocarbon receptor (AHR) may act as a potential repressor of GDNF expression.
Previous studies have shown that knocking out AHR upregulated vascular endothelial
growth factor (VEGF) expression and markedly enhanced the ischemia-induced
angiogenesis (Ichihara et al., 2019). Hence, inhibiting AHR may enhance GDNF synthesis
after injury.
We have previously demonstrated the upregulation of several genetic pathways
involved in trans-differentiation and reprogramming of Schwann cells into “repair” cells
in response to nerve injury to humans (Welleford et al., 2019). Nonetheless, the current
transcriptome analysis adds to our understanding of the reprogramming process of those
cells through mapping the expression of essential regulatory genes that are clustered to the
proliferation of those glial cells (figure 3.2). The transcript levels of 8 of those genes were
enriched (E2F1, IL1B, IL6, LYN, MYB, PRKCH, IDH2, and ADCYAP1R1) while the
expression of only 2 genes (SOX10, PLAG1) was significantly downregulated at 2 weeks
post-injury. The later genes were clustered as negative regulators of Schwann cells
proliferation (Fujiwara et al., 2014); thus, repressing their expression may have helped to
induce the proliferation of Schwann cells. Furthermore, several genes were significantly
expressed and involved in axonogenesis, axons regeneration and extensions, and enhancing
neural synaptic plasticity such as PLXNC1 (Chabrat et al., 2017), GRN (Rosen et al.,
2011), and SHANK3 (Huang et al., 2019) (figure 3.4, figure 3.5).
PD is a progressive neurodegenerative disease accompanied by the degeneration of
dopaminergic neurons within the substantia nigra of the midbrain. Approximately 10% of
the PD cases are familial with a spectrum of PD-causative genes that have been identified
(Ferreira & Massano, 2017). Through this study, we analyzed the transcriptional regulation
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of the major PD-related mendelian genes and the PD-risk loci (Hernandez, Reed, &
Singleton, 2016). A total of 8 PD-related genes (SNCA, DNAJC6, PLA2G6, LRRK2,
PDZRN4, SIPA1L2, MAPT, and GCH1) were differentially expressed. Most importantly
was the consistent downregulation of alpha-synuclein (SNCA) gene among the 6 subjects
(FC = -5.56, p =1.5 E-18, FDR = 2.5E-17). At least 30 mutations in the SNCA gene have
been found to cause PD. Two main types of alterations of the SNCA gene are related to PD
(Petrucci, Ginevrino, & Valente, 2016). In one mutation, the amino acid alanine is replaced
with threonine at protein position 53 or with the amino acid proline at position 30. These
mutations cause the alpha-synuclein protein to be misfolded and hazardously aggregates in
the cells. In the other type of alteration, SNCA gene is inappropriately duplicated or
triplicated, leading to an excess of alpha-synuclein deposition in patients with PD (Zafar et
al., 2018). It is unclear how SCNA gene causes PD, but alpha-synuclein proteins cluster
together to form Lewy bodies leading to selective death or impairment of neurons that
produce dopamine. There is evidence that inhibition of α-synuclein aggregation can
improve the survival of neurons after injury (Teil et al., 2020). To our knowledge, eight
transcription factors have been demonstrated to be involved in regulating SNCA
transcription. GATA2 and p53 promote SNCA transcription; PARP1, EMX, C/EBPβ, and
NKX6/1 repress it while ZSCAN21 and ZFN210 can have both effects; for review see
(Piper, Sastre, & Schüle, 2018). To further explore the signaling pathways involved in the
expression SNCA and the other PD-related gene in Stage II nerve samples, hundreds of
unique regulatory transcription factors were functionally mapped to be Parkinson’s related
genes through Reactome pathway database. 20 transcription factors were differentially
expressed and significantly correlated to the PD-related genes (figure 3.8). 8 transcription
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factors (EGR2, NBN, ZXDB, NRF1, ZNF792, ZBTB20, ZFHX2, and DRAP1) were
significantly correlated to the downregulation of SNCA expression. In particular, the
upregulation of ZNF792 (FC = 2.0, p =4.6E-6, FDR =1.8E-5) was significantly correlated
(r = -0.837, p = 0.037) to the repression of SNCA gene in stage II. This finding strongly
points to ZNF792 as a potential repressor of SNCA gene. Future studies using gene therapy
to target such repressors of SNCA may help reduce alpha-synuclein aggregation in the
neurons (Valente et al., 2020).

Conclusion

In summary, this study provides evidence that the sural nerve autologous implants,
which are harvested from PD participants two weeks after a conditioning injury, embrace
a repair phenotype consistent with a release of growth factors, a proliferation of Schwann
cells, axons regeneration, and enhancement of neural synaptic plasticity. We have also
demonstrated significant changes in several major PD-associated genes. We have
identified novel transcription regulators of several PD-associated genes, like SNCA, which
will expand our knowledge about the different molecular pathways involved in the
regulation of PD-causative genes. We believe that this transcriptomic analysis will be of
great benefit for future therapeutic strategies to reduce the levels of α-synuclein in PD and
other synucleinopathies.
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Table 3. 1 Mass and Freezing Time Delay of the nerve samples collected during Stage I
vs. Stage II.

STAGE I SAMPLES

Participants

Mass (g)

1

STAGE II SAMPLES

Mass (g)

0.0205

Freezing
Time Delay
(min)
16

0.0354

Freezing
Time Delay
(min)
41

2

0.0158

28

0.0301

108

3

0.0254

20

0.0613

64

4

0.0256

14

0.0363

52

5

0.0294

14

0.0757

39

6

0.0197

17

0.0256

50

Mean ± SD

0.0227±
0.0049

18 ± 5

0.0441 ± 0.0198

59 ± 25

Freezing Time Delay includes the gross dissection time during which fascicles were
separated from the whole nerve and the time required for fascicle segment implantation
into participants during Stage II.
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Figure 3. 1 Lesion-Freezing delay of the nerve samples collected during Stage I and
Stage II .
Freezing time delay was significantly longer (Paired two-tailed t-test: t(5)=4.863, p =
0.0046) for post-lesion nerve samples (59 ± 25 min; Mean ± SD) compared to pre-lesion
ones (18 ± 5 min).
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Figure 3. 2 Differentially expressed genes involved in regulating glial cell proliferation.
Abundance of the transcripts levels of 8 genes annotated with the positive regulation of
glial cell proliferation (GO:0060252). The two genes annotated (SOX10, PLAG1) with
negative regulation of glial cell proliferation (GO:0060253) were downregulated transcript
levels in stage II nerve tissue. Differential expression cutoff criteria were |log FC| >1, p <
0.05 and FDR <0.05).
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Figure 3. 3 Analysis of growth factors activity.
Differentially and significantly expressed growth factors defined under Growth Factor
Activity according to gene ontology (GO:0008083). Differential expression cutoff criteria
were |log FC| >1, p < 0.05 and FDR <0.05).
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Figure 3. 4 Analysis of the key genes involved in the axonal repair.

Heat map obtained for the differentially-expressed genes that are annotated with the
ontology terms: Regulation of Axons Regeneration (GO: 0045773) and Axons Extension
(GO: 0050772). The transcript levels were obtained from the sural nerve tissue of 6
participants during stage II surgery and compared to that of stage I. The expression of main
positive regulators of Axonogenesis. such as PLXNC1 gene, was upregulated at two weeks
after the initial nerve injury. Significant levels were determined at |Log FC| >1, p < 0.05
and FDR <0.05.
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Figure 3. 5 Analysis of neural synaptic plasticity two weeks after sural nerve injury.
There was a significant abundance of the transcript levels of the genes (SHANK3 and KIT)
that are positive modulators of the long-term neural synaptic plasticity in nerve tissue
obtained from all participants during stage II surgery. |Log FC| >1, p < 0.05 and FDR
<0.05).
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Figure 3. 6 Correlation matrix between significantly expressed TFs and growth factors in response to nerve injury
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Figure 3. 7 Comparison of the transcripts’ levels of differentially-expressed PD-related
genes.
Heat maps obtained from RNA-Seq data of stage II sural nerve tissue and compared to that
of stage I. The abscissa indicates the participants and ordinate indicates A) PD mendelian
genes and B) PD-Risk loci that were significantly and differentially expressed with
|log2FC| ≥ 1 and p-value < 0.05.
A)

B)
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Figure 3. 8 Identification of transcriptional regulators of PD-related genes.
The expression pattern of the differentially-expressed transcription factors (TFs) during
stage II was compared to that of PD-related genes. The Correlation matrix was mapped in
JMP Pro14 with |Pearson’s correlation| ≥ 0.8 and p-value < 0.05. Seven potential repressors
were significantly upregulated in coordination with the subsequent downregulation of 5 PDrelated genes, while 13 TFs were significantly downregulated in a strong correlation with
the suppression of the PD-related genes.
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CHAPTER FOUR: THE NEURO-AVATAR PROJECT

Abstract

The implantation of peripheral nerve tissue and cells provides anatomical and
functional restoration in a variety of CNS injury models. To date, the reported results of
implanting peripheral nerve cells within the brain environment have been limited to the
usage of rodent peripheral nerve tissue. Transplanting human peripheral nerve fascicles in
the dorsal striatum of rodents have never been examined experimentally. Herein, we describe
the survival, biodistribution, and host responses to human peripheral nerve tissue implants,
harvested from human donors according to the protocol developed for the Phase I DBS-Plus
clinical trial. Repair human Schwann cells (huSCs) persisted within the injured rat dorsal
striatum through 6 months after implantation and displayed restricted biodistribution within
the implantation site. Besides, histological comparison between injury-naive and
conditioned implants (14 days after injury) was also reported. Further, studying the bioresponse of the brain tissue, using proton magnetic resonance spectroscopy, displayed signs
of a positive influence of the PN implants on the integrity of the central neurons.

Introduction

Cell therapeutics have been one of the frontline approaches that aimed at promoting
neuron replacements or repair in the central nervous system (CNS). The introduction of a
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diversity of cell types, including transplantation of SCs, in the form of a peripheral nerve
(PN) implant or as an injected-purified cell suspension, has been examined as a therapeutic
strategy in various CNS injury animal models over the last three decades (Wiliams & Bunge,
2012). This experimental approach was recently implemented clinically in Poland, where
human SCs transplanted as PN implants showed indications for safety and efficacy in
subjects with spinal cord injury (Tabakow et al., 2014).
Our transcriptomic results reported in Chapter 3 add to our understanding of the
repair potential adopted by the human PN two weeks after an injury. Yet, we still needed to
assess the neurobiology of the conditioned PN implants following implantation in the
midbrain. To our knowledge, all preclinical data supporting the safe and effective use of SCs
upon transplantation, in the form of PN implants, into the CNS were almost exclusively
employed in rodent‐derived cells (Bastidas et al., 2017). To date, no research study has
examined the effects of human SCs when transplanted into the brain. Thus, to better learn
about the survivability, distribution, and interaction of human SCs, when transplanted in the
form of PN implants, we designed the Neuro-Avatar project. This xenotransplantation
project aimed to examine cellular function and host response to human SCs when
transplanted into the dorsal striatum of the athymic nude rat. Athymic nude rats are an
immunodeficient strain of Sprague-Dawley rats with a reduced immune rejection of foreign
tissue (Hanes, 2006). To better characterize the transplantation paradigm used in DBS Plus
clinical trial, we utilized human PN fascicles harvested during Stage I and Stage II surgeries
and implanted them in the brain of athymic nude rats. First, we studied the bioavailability
and distribution of human SCs at two weeks and six months post-transplantation. Then, we
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assessed the host bio-response to the xenograft using the modern applications of in vivo 1H
Magnetic resonance spectroscopy (MRS) (Ligneul et al., 2019).

Experimental Design and Procedures

Four human participants undergoing the DBS Plus trial have donated sural nerve
fascicles. Grafts from the donated nerve fascicles were implanted in a total of 16 animals: 8
brains were collected at two weeks post-surgery and 8 were collected six months postsurgery. Within each group of 8 animals, 4 were implanted with human nerve tissue from
Stage I surgery (injury-naive tissue), and 4 received nerve tissue from Stage II surgeries (in
vivo- conditioned tissue).

Harvesting of Human Peripheral Nerve Implants

Experimental procedures, including handling and transplantation of human
peripheral tissue, were approved by the IRB (B18-3211-M) of the University of Kentucky.
Human peripheral nerve fascicles were obtained from 4 human subjects (aged 45-70 years)
who are undergoing DBS-Plus surgery for Parkinson’s disease. The sural nerves were
dissected, and the nerve fascicles were collected from stage I and stage II. The nerve fascicles
were collected in sterile conditions, placed on ice, and transported from the operating room
to the laboratory for grafting. Up to 9 nerve fascicles were harvested from 1 cm section of
the sural nerve during stage I surgery and two weeks later during stage II surgery.
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Animal Care

All animal procedures were approved by IACUC of the University of Kentucky and
performed per NIH guide for the care and use of Laboratory animals. 23 adults male athymic
nude male rats (Hsd:RH-Foxn1rnu) were obtained from Charles River Laboratories,
Chicago, IL. On average, the animals weighed 225g ± 20, were at eight weeks of age, and
were housed in micro-isolated cages and kept in a room designated for immunodeficient
rodents with a 12-hr light/dark cycle. Autoclaved food and water were available ad libitum.
Cages and bedding were changed every three days. Clinical observations, as well as health
and mortality records, were noted.

Animal Surgery

The surgical field was prepared by laying out a sterile surgical drape over a preheated
surgical warming pad set to 38-40 °C. The sterile, empty surgical cannula was mounted to
the arm of the stereotactic frame. This cannula was a 20 gauge needle with the tip blunted
and smoothed with a Dremel tool and an inner stylet of 0.1 mm diameter. Anesthesia was
induced using 5% isoflurane with supplemental oxygen in an anesthesia induction box. After
anesthesia induction, animals were secured to the stereotactic frame using a tooth bar and
anesthesia nose cone with 2.5% isoflurane with supplemental oxygen. Ear bars (45° NonRupture tip) were placed securely in both auditory canals and adjusted until the animal was
symmetrically secured to the stereotactic frame. Animals were kept on surgical warming
pads during and after surgery. The dorsal surface of the animal’s skull was shaved using an
electric razor from brows to ears. Next, the skin was swabbed two times with cotton swabs
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soaked in betadine solution followed by a wipe-down with two alcohol pads. After
anesthesia induction, the animal was treated with the following: Rimadyl (10 mg/kg, SQ),
Buprenorphine SR (1 mg/kg SQ), and Baytril (5 mg/kg IM). After making the skin incision,
Bregma was located on the skull surface and a burr hole was made over the right stratum (1
AP, -2.5 LM) and the dura carefully broken. The cannula containing the PN implants, was
lowered slowly at a rate of ~1 mm/minute. Once the target was reached (-4.5 DV), a 1 mm3
of human PN implant was implanted in the right striatum. The cannula was removed slowly
and the burr hole was sealed using bone wax. The surgical incision was stapled. The animals
were transferred for recovery on a surgical warming mat.

Histological Processing

At the endpoints (2 weeks and six months post-transplantation), animals were deeply
anesthetized

using a

single

dose

of

pentobarbital

(100

mg/kg

IP)

and

then transcardially perfused with at least 250 mL of normal cold saline followed by 180 mL
of 4% Paraformaldehyde (PFA). The brain was extracted and postfixed with 4% PFA for at
least 24 hours. Following post-fixation, the implantation site was identified and cut into a 1
cm section in brain mold and cryoprotected in 30% sucrose for three days. Cryopreserved
brains were cut coronally into 40 µm thick sections and stored in 30% sucrose solution with
0.1% sodium azide until being stained.
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Immunostaining

To identify the transplanted human peripheral nerve cells and examine their
interaction with the host CNS, immunostaining with antibodies against Human Nuclear
Antigen (HNA) was employed. Tissue series from the transplanted brain sections were
subjected to anti-HNA antibody together with DAPI (4′,6-diamidino-2-phenylindole). The
primary antibody used was Mouse Anti-human HNA (1:500; Catalog#: ab191181, Abcam,
Cambridge, MA). The fluorescent secondary antibody was Alexa conjugated goat Antimouse IgG (1:500; Catalog#: ab150113, Abcam, Cambridge, MA). To ensure the specificity
of observed immunostaining, both positive and negative controls were included during
staining. Negative controls consisted of the incubation of the primary or secondary
antibodies alone, in addition to a non-grafted and intact rodent brain collected after 6 months
of the experiment. Positive Controls consisted of incubation of sections of human sural nerve
collected during both stage I and stage II surgeries. The brain sections were transferred from
their wells and washed once with PBS. The tissue was permeabilized using 0.2% Triton X100 for 5 minutes and then washed with PBS once. The slides were blocked with 5% goat
serum, 1%Triton X-100 for 1 hour. Afterward the slides were incubated with the primary
antibody in PBS, 0.1% goat serum overnight at 4’C. The next day, the slides were washed
with PBS, 3x5 minutes, and incubated with fluorescence-conjugated secondary antibody in
PBS, 0.1% normal serum for 1-2 hours at RT in the dark. Finally, the slides were rinsed in
PBS, mounted on coverslips, and examined under a fluorescent microscope.
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Magnetic Resonance Spectroscopy

Magnetic Resonance Spectroscopy is possible on any nucleus producing a magnetic
moment. The metabolically active proton nuclei (1H) is the most sensitive for NMR, and it
allows us to detect a large number of important amino acids and metabolic pathways’ end
products like N-acetyl aspartate (NAA) and Creatine (Cr) /phosphocreatine. In healthy brain
tissue, the most prevalent resonance originates from the methyl group of NAA at 2.02
ppm (Moffett et al., 2007). The chemical shifts are referenced in regard to that of 3(trimethylsilyl)1-propanesulfonic acid at 0.00 ppm. NAA is exclusively localized in the
central as well as the peripheral nervous systems. NAA has been used as a marker for viable
neurons as it is only found in neurons, and its concentration decreases in the
neurodegenerative diseases which affect the CNS (Schuff et al., 2006). The NAA
concentration is not uniform and varying between gray matter (8-11 mM) and white matter
(6-9 mM) (Moffett et al., 2013). The methyl and methylene protons of creatine and
phosphocreatine resonate at 3.03 ppm and 3.93 ppm. Since the sum of both forms, total
creatine (tCr), is constant in adulthood, the later can be used as a suitable in
vivo concentration reference. Glutamate and Glutamine peaks were determined at 2.1-2.5
ppm and 3.7 ppm, respectively. Brain morphology and metabolism were assessed using
T2WI

magnetic

resonance

and

imaging

MRI

and

MRS

(7-tesla

Horizontal

bore magnet; Bruker/Siemens scanner) at three months post-grafting in Neuro-Avatar
animals. Two animals were used for MRS studies at three months post-grafting. The first
one was a neuro-avatar athymic rat that has received a stage II human nerve tissue implanted
into the right dorsal striatum. The second animal was a sham animal where a cannula with
PBS, and no nerve implant was inserted into its striatum. Rats were anesthetized using 2%
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isoflurane. The heads of the rats were fixed in a body retainer, the respiratory rate
was monitored, and the body temperature was maintained at 37 oC with a body heating
pad. Spectra were acquired at TR/TE/NS = 2500/3/200 for ipsilateral as well as the
contralateral striatum with the voxel (volume = 3×2×3 mm3) placed just next to the
implantation trajectory. Ipsilateral metabolic concentrations were normalized to that of the
contralateral (intact) hemisphere before comparing the two treatment groups.

Results

Accuracy and Precision of Stereotactic Surgical Implantation Procedure

Gross histology of 5 transplanted brains showed that some of the transplantation
trajectories did not reach the deep targets in the dorsal striatum. Some of the trajectories
were deflected when passing through the corpus callosum. This could partially be caused by
the tract made by the blunted cannula in the brain tissue leading to lateral deviation of the
trajectory in fibers-dense brain areas like in corpus callosum. However, the grafted brains
with deviated trajectories were not excluded from the final analysis since the main objective
of the experiment was to assess the viability of the human nerve cells post-implantation in
the central nervous system environment.

Long-Term Survival Of Human Sural Nerve Implant After Implantation

Human Schwann cell transplantation, in the form of PN implants, in the brain of
injury rats was followed by analysis for evidence of the long-term survival in vivo (figure
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4.1). At two weeks post-implantation, animal brains implanted with pre-degenerated PN
implants (Stage II) contained a higher count of +HNA cells than the animals implanted with
PN tissue that were harvested from stage I (figure. 4.2). Second, transplanted +HNA human
cells derived from stage I PN tissue significantly are significantly reduced 6 months after
transplantation. However, the viability of human cells was significantly higher in animals
receiving implants from stage II rather than from Stage I samples (figure 4.3). In addition to
that, the cystic cavity and the surrounding edema were smaller at 6 months post-implantation
from stage II implants.

Brain Reaction To Human PN Implants

Brain morphology and metabolism were assessed using an in vivo proton magnetic
resonance spectroscopy (MRS). Proton spectra (Figure 4.4) were acquired in a cubic
volume of 18 mm3 in the right striatum of sham and avatar groups, and the concentration
ratios of N-acetylaspartate/choline (NAA/Cr) and other metabolites (Myo-inositol (Ins),
Taurine (Tau)) were determined after identifying their respective peaks on the spectra
(Figure 4.5). One animal was randomly chosen from each group to undergo the MRS study
at three months of the surgery. Brain T2WI showed a similar insertion trajectory with mild
hyperintensity at the implantation socket of the avatar brain. The N-acetylaspartate/choline
(NAA/Cr) ratio, a neuronal marker, measured by MRS inside the striatum of the avatar brain
showed a mild increase around the implant tip. The astrogliosis marker, Ins, was slightly
increased in comparison to the sham animal. Tau, a marker of inhibitory neurons, was
decreased in the striatum of the avatar animal.
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Discussion

In response to peripheral nerve injury, Schwann cells transdifferentiate and gain new
potential to proliferate, survive, and migrate in a hypoxic PNS environment (Chang et al.,
2011; Yao et al., 2016; Yu et al., 2012). Our goal is to identify the cellular viability and
molecular changes after transplanting conditioned and pre-injured human peripheral nerve
implant in the deep brain areas. To our knowledge, this is the first study that utilizes fresh
and in vivo conditioned human peripheral nerve implants to the rat’s striatum. To avoid
rejection of the nerve xenografts, this Neuro-Avatar project used athymic nude rats which
are immunocompromised animals and have been successfully utilized in xenotransplantation
research (Bastidas et al., 2017; Hanes, 2006). Human sural nerve tissue, donated by patients
with PD participating in our DBS Plus clinical trial, were implanted in the dorsal striatum of
the animals. We have shown that huSCs remained viable in the dorsal striatum up to six
months post-transplantation (longest period examined). The implanted human derived cells
demonstrated limited migration outside the grafting socket, a low proliferation rate, and no
tumorgenicity features. When compared to Stage I implants, the Stage II implants displayed
a higher cell count and viability in vivo. This is consistent with previous studies that indicated
following a nerve injury, the distal stump undergoes Wallerian degeneration which
optimizes cells’ long-term viability and endurance (Gordon, Wood, & Sulaiman, 2019; Yang
et al., 2008).
In this study, we report the implementation of T2WI MRI and proton MR
spectroscopy to measure the biochemical response of the host striatum to conditioned-human
(Stage II) PN implants. Brain MRS is a non-invasive method to analyze the concentration of
metabolites in the cerebral and deep brain areas (VAN ZIJL & Barker, 1997). This technique
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allows us to acquire noninvasive metabolic data and help to monitor subtle changes in health
and disease states in humans as well as in animal models (Bozza et al., 2010; Cho, Choi,
Lee, & Kim, 2003; Manganas et al., 2007). In comparison to the sham group, we observed
that the relative concentration of NAA was increased around the implant and at the borders
of the substantia nigra. N-acetylaspartate has been used as an in vivo biochemical marker for
neurons integrity and neurogenesis (Moffett & Namboodiri, 1995; Moffett, Ross, Arun,
Madhavarao, & Namboodiri, 2007). The observed increase in NAA levels indicates
enhancement of neuronal integrity that is consistent with the RNA-Seq analysis findings
reported in Chapter Three, which demonstrated that pre-degenerated (Stage II) PN implants
embrace a transcriptome profile that drives neurogenesis and axonal regeneration. We also
observed a slight increase in Ins surrounding the implant, which is consistent with predicted
gliosis (Haïk et al., 2008) produced by host astrocytes in response to the implantation
procedure (Reier, 2012). However, this gliotic reaction was not noticeable on T2WI images,
in contrary to other studies which reported significant CNS gliosis in response to fetal nigral
grafts (Barker, Dunnett, Faissner, & Fawcett, 1996; Chi & Dahl, 1983; Lee et al., 2008).
These results support incorporating MRS analysis in the DBS Plus clinical trial to improve
our evaluation of brain response to PN implants in human subjects.

Conclusion

In conclusion, throughout this study, we investigated the viability and function of
human Schwann cells following implantation of human nerve implants into the dorsal
striatum. We have demonstrated that sural nerve implants collected from PD patients can
persist long-term after transplantation (up to 6 months). The conditioning injury to the sural
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nerve, induced during stage I of DBS surgery, incites the Wallerian degeneration
processes in vivo; thus, prompting the proliferation of huSCs and enhancing their survival
potential when collected at two weeks post-injury during the Stage II surgery of DBS
procedure. We also demonstrated that nerve implants lead to striatal cell protection and
central axons growth support. The histological and in vivo spectroscopy results do not
display changes indicative of toxicity while showing signs of host striatal environment
reacting positively to the nerve implants following implantation. Future studies employing
transplantation of proregenerative nerve tissue in the transgenic animal model of PD will
help us understand how such cell-based therapy can support the nigrostriatal cells in a
disease state.
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Figure 4. 1 Gross histology of Avatar brain.
A) Nissl stained-coronal section of 40 μm thickness with human PN implant located in the
right striatum (black arrow indicates the transplantation trajectory). B) MRI coronal section
of the implantation trajectory within the striatum.

A)

B)
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Figure 4. 2 Human PN derived cells remain viable in rat brain.
The immunofluorescence staining results showed that the HNA labeled cells remain viable
up to 6 months post-transplantation (longest period examined). HNA(green), DAPI (blue).
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Figure 4. 3 Survivability of the implanted autologous PN-derived cells.
Implanted PN cells survived for 6 months post-implantation in the rat brain. There is greater
viability when the cells were transplanted from Stage II (in vivo pro-regenerative or
conditioned tissue) in comparison to Stage I cells. At two weeks following implantation into
the striatum, nerve implants collected from Stage II DBS Plus displayed a significantly
higher count of HNA positive SCs, compared to nerve implants harvested from Stage I
surgery. Stage I implanted cell count was significantly decreased six months postimplantation. At six months, human SC viability was significantly higher in animals
receiving implants from stage II compared to Stage I. Statistical significance indicated a
*p<0.05 or **p<0.01.
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S ta g e II

Figure 4. 4 In vivo 1H MR spectroscopy analysis of brain metabolites.

(A) Spectra obtained and brain MRI images of the sham and human PN transplanted groups, and the relative amounts of Nacetylaspartate (NAA), Myo-inositol (Ins), Glutamate (Glu), Taurine (Tau), and creatine (Cr).
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Figure 4. 5 Concentration ratios of brain metabolites as identified by 1H MRS.
The relative concentrations in the grafted striatum were compared to the intact contralateral
side within each group (N=1). An increase of the neuronal marker (NAA) as well as a mild
increase in the gliosis metabolite (Inositol) was observed surrounding the PN implant in
the avatar group.
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CHAPTER FIVE: DBS PLUS CLINICAL TRIAL

Introduction

With no known cure, disease modifying therapies are one of the greatest unmet
medical needs in the treatment of neurodegenerative diseases like Parkinson’s disease (PD)
(Kalia, Kalia, & Lang, 2015). Prior cell therapies investigated for replacing degenerating
dopaminergic cells in the substantia nigra pars compacta (SNc), including fetal nigral cells,
autologous carotid body cells, and bone marrow-derived mesenchymal stem cells, have
failed to alter the progression of the disease (Yasuhara, Kameda, Sasaki, Tajiri, & Date,
2017). On the other hand, direct administration of non-neuronal cells that can deliver
trophic factors has demonstrated therapeutic potential in protecting the sick neurons and
possibly ameliorating the toxic environment in the brain (C. Chen et al., 2020). In 2013,
our research group initiated a clinical trial to investigate the hypothesis of using
reprogrammed Schwann cells (SCs), in a form of autologous peripheral nerve (PN)
implants, to deliver crucial repair molecules to the degenerating dopaminergic neurons in
PD patients undergoing DBS surgery (a procedure we have termed DBS Plus) (van Horne
et al., 2017). This clinical study was the first to investigate the use of autologous PN tissue
implants in conjunction with DBS, an FDA-approved adjunctive therapy to treat the
symptoms of PD. The main goal of the initial pilot study was to determine the safety,
feasibility, and tolerability of implanting PN implants at the time of DBS surgery. Eight
participants (6 males and two females) were included in the first pilot study, which
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demonstrated safety and feasibility of implanting sural nerve tissue containing autologous
SCs into the SNc from conditioned PN tissue.
To further validate the safety and to explore the potential “open label” efficacy of
this therapeutic approach, we have optimized the sample size in our ongoing studies
(clinicaltrials.gov, registration no. NCT02369003). The study reported here includes
participants with PD who elected to receive DBS plus pre-injured sural nerve tissue into
the SNc with targeting of DBS leads to the internal segment of the Globus Pallidus (GPi).
One benefit of this approach is that the location of the DBS leads is remote enough from
the SNc tissue implants so that they can be readily visualized with MR imaging. We
continue to investigate questions regarding dosing and optimization of bilateral placements
of the PN tissue implants to help lay the foundation for a blinded Phase IIa trial to optimize
the efficacy of the combined DBS and cell-based intervention.

Patients Selection

This clinical study is a part of an open-labeled Phase I clinical trial
(clinicaltrials.gov, registration no. NCT02369003) conducted by the Brain Restoration
Center at the University of Kentucky Medical Center. The study aims to investigate the
safety, feasibility and motor outcome of the DBS Plus intervention in two groups of PD
participants. Group A includes participants (N=18) who received Five, 1 mm3 sections of
pre-injured sural nerve tissue into the SNc. Group B participants (N=9) received a double
dose (2 sets of Five, 1 mm3 segments of nerve fascicle) of the sural nerve tissue. Both
groups of participants met the inclusion and exclusion criteria described in Chapter Two
and consented to receive DBS targeting bilateral GPi plus the designated cell therapy. For
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the control group, we collected UPDRS III OFF-medication scores of patients with PD
(w/o any history of surgical intervention) from the PPMI Database (Parkinson’s
Progression Markers Initiative). We collected UPDRS III data for 80 control subjects,
matched by age (45-75 years) and disease severity (Baseline OFF UPDRS III 30, Hoehn
& Yahr II-IV), for whom at least two years of follow-up was available. Since no OFFStimulation scores were reported in the database for PD subjects who elected to receive
DBS, such a group of subjects (+DBS, w/o implant) was not included in our comparison
analyses. We compared UPDRS III total OFF Medication/ OFF Stimulation scores,
parkinsonian motor subcomponents, change from baseline, striatal reserve measured by
Levodopa Response (OFF-ON difference), and adverse events at the end of one and two
years of clinical follow up. The study was approved by the institutional IRB and Ethics
committee.

Statistical Analyses

The statistical analyses and data plotting were performed using GraphPad Prism 8.
The quantitative data were plotted using mean  SEM. Analysis of the motor scores
between the groups at different time points was done using a Two-way ANOVA followed
by Tukey’s multiple comparison test. A comparison between the lateralized scores at the
Two-year time point was made using Wilcoxon Signed-Rank test. A multiple comparison
test was used to compare the motor subcomponents of the UPDRS III scale. A Spearman
correlation was used to test the relationship between the Levodopa Response at baseline
and the Change of the OFF Score at the post-op follow up examination.
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Results

Patient Summary

Twenty-seven participants (20 males and 7 females) met the criteria for
participation in the study (Table 5.1). 18 participants of group A and 9 of group B were
randomly assigned to receive unilateral implantation of single and double dose of PN
implants respectively. The mean age (SD) of group A participants was 62.9 ± 8.1 years,
and the mean disease duration was 9.3 ± 4.4 years. The mean age of group B participants
was 61.88 ± 6.66 years, and the mean disease duration was 9.3 ± 4.18 years. The baseline
UPDRS III OFF scores of group A participants ranged from 20 to 56, while those of group
B participants ranged from 22 to 75. One participant of group A has failed to follow up
while another participant has sadly passed away due to non-study related causes 20 months
post-surgery. Hence, a total of 16 participants of group A have completed their follow ups.
Only 8 participants of group B were able to complete their follow up assessments at the
12-month time point. For monitoring safety and adverse event reporting, each participant
was evaluated by a movement disorder specialist at the University of Kentucky Medical
Center and was in close communication with our study team throughout the study.

Safety of DBS Plus

All adverse events were submitted to and reviewed by the Data and Safety Monitoring
Board (DSMB) at the University of Kentucky. One adverse event, superficial cellulitis
around the ankle incision, was related to the transplantation procedure and was graded as
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mild. The infection was treated with oral antibiotics. Most of the participants complained
of ankle paresthesia and numbness, which was expected and consented as a result of
sectioning the sural nerve. Three adverse events (urinary retention, headache, and dyspnea)
were mild, related to the DBS surgery and the general anesthesia (but not to the
implantation procedure), and resolved without further intervention. Three events, included
falls, were considered to be mild, not serious, and not related to the implantation procedure
as well. One event, hypomania, was mild, not serious, and was related to DBS stimulation
and resolved promptly after changing the stimulation of the more proximal set of contacts
of the stimulating electrodes. With regards to DBS surgery, there were no observed
infections, hardware malfunctions, or skin erosions. Concerning feasibility, all participants
underwent successful sural nerve resection and tissue implantation without complications
or significant delay.

MRI Imaging

Post-op imaging was performed using a 1.5T MRI to verify targeting of the DBS electrodes
and the tissue implant location. The MRI images were performed within 48 hours postsurgery. There was no evidence of edema on the T2 weighted images (T2WI) and no
enhancement on the T1WI contrast images. Post-op MRI images were fused to pre-op CT
scan data and the implantation trajectories were mapped using Lead-DBS software (Hanes,
2006) to verify the placement of the electrodes and the tissue implants in all participants
(figure 5.1). There was no evidence of stroke, hemorrhage, or brain deviation resulting
from the procedures.
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Motor Outcomes

Analysis of the UPDRS III motor scores at a two-year follow up of participants
who received DBS plus a single dose of PN implant (Group A) showed a remarkable motor
improvement in comparison to the control PD group (Table 5.2). We observed a substantial
improvement in motor score at the 6 month time point (UPDRS reduction of 7.82). This
improvement in motor score persisted for 24 months post-surgery. This change from the
baseline was significant (p<0.0001) when compared to Control PD subjects who continued
to progress clinically and scored on average 6.53  10.6 more points (figure 5.2).
Also, we report here UPDRS III scores of the participants who received DBS plus
the double dose of tissue implants (Group B). Out of 9 participants from Group B who
were consented and enrolled in the study, only one subject failed to follow up at a 12-month
time point. This group of participants had on average an improvement in their motor scores
by 8.25 points ± 11.46 one year after the surgery (Table 5.2). Although the motor outcome
profile of Group A was similar to that of Group B, the latter group scored 1.62 points less
at six months following the surgery (UPDRS OFF Change: -9.44 vs. -7.82 points) (Figure
5.3).
We further explored the UPDRS part III data by performing subgroup analysis of
Group A participants to investigate potential differences among symptom subsets,
including tremor, rigidity, bradykinesia, and axial symptoms (speech, facial expression,
gait, posture, postural instability, and body bradykinesia), and between lateralized scores
relative to implant placement (ipsilateral vs. contralateral). Analysis of the lateralization
effect of the tissue implants showed a significant overall reduction in the UPDRS III motor
on the side contralateral to the cell implants vs the ipsilateral side (p= 0.0273; see Figure
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5.4). Subgroup analysis of the parkinsonian motor signs demonstrated significant
improvements in tremor and bradykinesia and minor improvements in rigidity and axial
symptoms (Figure 5.5).

Correlation between Levodopa response at baseline and motor outcome

The Levodopa response was determined by the difference between the UPDRS III
OFF and ON medications state. 16 subjects of group A, who completed their two-year
follow-ups underwent the levodopa challenge test. Participants were assessed after 12–14
h without anti-parkinsonian medication and then given their usual prescribed dose of
levodopa/carbidopa tablets and they are re-scored 2 hours afterwards. In Figure 5.6, the
analysis revealed that the motor performance postoperatively had a significant positive
correlation with the levodopa response at baseline (r = 0.6794, p<0.0038). Participants with
higher Levodopa response at the baseline tended to score less at two years after the surgery.
We also intended to assess how each participant scored clinically relative to the thresholds
for clinically important difference (CID). According to Shulman et al., (Shulman et al.,
2010) minimal, moderate, and large CIDs are 2.5, 5.2, and 10.8 points from baseline,
respectively. In total, 12 out of 16 participants (75%) scored about the threshold for
minimal CID.

Discussion

The results of this study support the concept of combining cellular therapy with
DBS to alter the progression of PD. This hybrid approach of merging a direct delivery of
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biological therapy with the standard DBS surgery is anticipated to expand our
understanding of the disease pathology and introduces a new era for disease-modifying
treatments (Rowland et al., 2016). Research evaluating two main strategies for celltransplants in PD, using fetal nigral grafts or induced pluripotent stem cells, are ongoing in
the TRANSEURO trial and GForce-PD initiative (Barker, 2019; Z. Chen, 2018). Their
concept is based on replacing the degenerating dopaminergic neurons by implanted
neurons, which might be able to synthesize dopamine in vivo. Nevertheless, these strategies
have faced serious ethical and safety obstacles like the formation of teratomas, and
treatment-induced dyskinesia (Christophersen et al., 2006; Knoepfler, 2009; Sonntag et al.,
2018) as well as some frustrating motor results (Graff-Radford et al., 2006). In comparison,
the cell-based therapy used in our DBS Plus trial involves a neurorestorative approach to
repair the nigrostriatal system. This research investigates the use of autologous peripheral
Schwann cells as a source of regenerative growth factors to restore and protect the
degenerating dopaminergic cells rather than replacing them. The main advantage of our
approach is that the patients will be providing their autologous cells, which are harvested
and implanted simultaneously with the standard DBS symptomatic treatment.
This Phase I clinical trial was initially designed to test the safety and feasibility of
implanting autologous peripheral nerve tissue into the substantia nigra in combination with
DBS in patients with PD. Since the ethical requirement of beneficence renders the
exclusion of the standard of care (DBS) unethical, we could not enroll in our clinical study,
a control cohort of PD patients. Nonetheless, we compared the motor outcome of our study
participants to retrospective cohort patients collected from the PPMI database. This
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retrospective cohort included age and baseline-matched subjects with PD, who have
received no surgical intervention, including DBS.
The DBS procedure is approved for patients who have had PD for at least four years
and whose symptoms are adequately responsive to medications. This surgical intervention
alone has turned out to be a relatively safe surgical procedure to treat advanced PD
symptoms. The adverse events of the combined therapy reported in this study were similar
to the DBS surgery without transplantation (Bratsos, Karponis, & Saleh, 2019). Only one
long-term adverse event, local cellulitis, was related to our implantation procedure and it
resolved with oral antibiotics. Additionally, brain mapping and MRI imaging post-op
showed accurate targeting of the tissue implants in the substantia nigra with no evidence
of edema, hemorrhage, or signal abnormality along the graft trajectory. Additionally, we
did not observe neither off nor on-therapy dyskinesias in our participants throughout the
follow-up visits. Although these patients have received DBS, we argue that implantinduced dyskinesia is not masked by the electrical stimulation since the DBS target (GPi)
is distant (5 mm) from the implant location (SNc) and the patients are evaluated 12 hours
off stimulation.
In regards to the motor outcome, there was an overall decline in UPDRS III scores
(-7.82, ± 9.1) during the first six months of the surgery in participants who received DBS
plus the five pieces of sural nerve tissue. This reduction appears to be slightly greater ( 9.44, SD ± 9.3) in participants who received the double dose of tissue implants. Interestingly,

it looks as though the improvement in UPDRS III scoring tends to be relatively stable for
two years after surgery. In comparison, the disease continued to progress in the control PD
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group who scored an increase of 6.53 points (SD ±10.6) at the two-year follow up similar
to what was reported in another study (Vavougios et al., 2018).
A comparison between ipsilateral versus contralateral UPDRS III motor scores
showed improvements on both sides but a statistically significant difference in the scores
contralateral to tissue implant location. The mild ipsilateral improvement, which has been
reported by other surgical interventions for PD (Walker, Watts, Guthrie, Wang, & Guthrie,
2009), might be due to regeneration of some non-decussating fibers connecting the
midbrain and the striatum at the implanted side.
In depth analysis of the UPDRS motor subcomponents showed that the most
significant improvement was in the tremor and bradykinesia domains. We do not anticipate
this improvement could be due to DBS therapy as DBS was turned off for 12 hours before
motor testing. This should be sufficient time for most therapeutic effects of the DBS
electrophysiological stimulation to dissipate (Temperli et al., 2003).
To assess the importance of changes in UPDRS III scores clinically we evaluated
our results relative to the CID thresholds as described by Shulman and his team (Shulman
et al., 2010). Out of 16 participants who received bilateral DBS plus a single unilateral cell
implant, 11 (69%) improved clinically above the minimal CID, three were stable, and 2
participants scored higher (worse).
Lastly, we analyzed the change in UPDRS III OFF score after two years in
correlation with the absolute value of Levodopa response at baseline. The acute motor
response to Levodopa following a minimum of 12 hours washout has been used as a guide
in managing medical or surgical decisions in PD (Ganga et al., 2013). However, recent data
have demonstrated that the amplitude of motor response to Levodopa tends to increase with
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increasing disease duration and progression (Pieterman, Adams, & Jog, 2018). In the group
of participants who completed the two year follow up, there was a significant positive
correlation between the amplitude of Levodopa Response at baseline and the reduction
seen in the UPDRS III Off score. This analysis was consistent with the clinical
improvement recognized in those subjects who scored beyond the threshold of the minimal
clinically important difference. The results of this correlation may help us to better
determine those participants who are expected to respond to this cellular therapy in future
enrollments.
One limitation of our study is the lack of a DBS only treatment group. It is difficult
to recruit patients who receive the standard DBS surgery and to consent them for testing
while being off stimulation and off medication for 12 hours. Another limitation is the lack
of in vivo functional data to better assess the viability of the implanted SCs and their
biological effects. The current FDA guidelines restrict any kind of in vitro manipulation or
labeling of the cell implant tissues. However, an ongoing collection of post-op DaTscans
should further help us evaluate the impact of the implants on regenerating the dopaminergic
projections to the striatum.

Conclusion

In summary, this clinical study is exceptional because it provides prospective data
on using cellular therapy in combination with DBS treatment in humans. Besides, this is
the first study to investigate the influence of peripheral nerve cell implants in modifying
the disease progression in PD. The results support the clinical trial’s primary aim, which
is to deliver pro-regenerative PN cells to the substantia nigra of patients with PD.
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Throughout the analysis, we have demonstrated a favorable profile of extended safety and
tolerability of the combined therapy. Our results have also shown the potential efficacy of
the pre-conditioned implants in reducing the severity of the motor impairment in PD.
There was a remarkable restoration of motor function, mainly on the side
contralateral to the implant location, as assessed by the standard UPDRS scale part III.
Most importantly, this restoration of function was not temporary, and it persisted up to two
years post-intervention. Overall, the findings presented in this study worth further clinical
investigation to better understand how PN cell implants were able to interact with the
degenerating central neurons and restore the structures and functions of the nigrostriatal
system.
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Table 5. 1 Demographic characteristics of the study subjects.
Age, Baseline scores, and duration of diagnosis are represented as Mean  SD.

Group A

Group B

Control PD

DBS Plus Double Dose
of Unilateral Implant
(N=9)
7

(N=80)

Male

DBS Plus SingleUnilateral Implant
(N=18)
13

Female

5

2

_

Age (year)

62.9 ( 8.1)

61.9 ( 6.7)

59.4 ( 7.9)

Baseline UPDRS III Off

38.4 ( 11.3)

42.8 ( 15.7)

34.4 ( 4.2)

Duration of Diagnosis (year)

9.3 ( 4.4)

9.3 ( 4.11)

> 5 years

_

Table 5. 2 Change from the baseline of UPDRS III OFF scores
Comparison of the change of UPDRS III OFF scores from the baseline of DBS plus a
single dose of unilateral cell implants (group A) vs Control subjects with Parkinson’s
disease. (Mean  SD)

Follow Up

Control PD

TIMEPOINT (months)

DBS Plus

P-Value

(Group A)

6

0.46 ( 6.7)

-7.82 ( 9.1)

0.0129

12

3.42 (10.4)

-8.33 ( 9.3)

<0.0001

18

3.23 ( 9.6)

-7.00 ( 9.1)

0.0013

24

6.53 ( 10.6)

-9.56 ( 10.7)

<0.0001
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Figure 5. 1 3D Mapping of the implant location
Coronal and anterior 3D view of the basal ganglia. The implantation trajectory and the final
target of the tissue implants into the unilateral substantia nigra (in yellow) was mapped in
Lead-DBS software. Globus Pallidus external segment (GPe), Globus Pallidus internal
segment (GPi), Red Nucleus (RN), Substantia Nigra (SN), Subthalamic Nucleus (STN).
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Figure 5. 2 Motor Outcome
Motor evaluation of the study participants who received DBS Plus single dose of cell
implants into SNc (group A) in comparison to Control PD. (*<0.05. **<0.01,
****<0.0001).
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Figure 5. 3 Implant Dosage Motor Outcome
Motor Evaluation of Study participants who received GPi DBS plus double dose cell
implants into the substantia nigra unilaterally.
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Months

Figure 5. 4 Lateralization response to the cell implants.
Analysis of the Change in UPDRS III Off scores in participants who received bilateral GPi
DBS plus single cell implants showed a significant improvement on the side contralateral
to the cell implants vs the ipsilateral side (t-test (n=16); p-value=0.0273).
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Figure 5. 5 Parkinsonian Subcomponents Analyses
Analysis of the motor subcomponents of UPDRS III scale in 16 participants of group A at
two-year follow up. The significant improvements in the OFF scores were in Tremor and
Bradykinesia, whereas Rigidity and Axial impairments showed some mild changes.
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Figure 5. 6 Correlation between Implant Response and Levodopa Response at baseline
Correlation between the Levodopa Response at baseline and the Change in the motor scores
at: A) 24 months of participants who received DBS and a single dose of nerve implants in
the substantia nigra B) 12 months of participants who received DBS and a double dose of
nerve implant. CID: Clinical Important Difference. Minimal (2.5 points), moderate (5.2
points), and large (10.8 points) CIDs are indicated. Each symbol represents a different
participant.
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DISCUSSION AND FUTURE DIRECTIONS

PN tissue as a source of cell-based therapy for neurodegenerative diseases has been
investigated experimentally over the last four decades, and the past few years have shown
renewed progress in its use in clinical trials. The research work demonstrated through this
dissertation aimed to test how manipulating PN tissue can deliver vital therapeutic agents
to CNS neurons to stop, slow, or reverse degenerative processes. Hence, PN tissue may
have the ability to alter the progression of neurodegenerative diseases and contribute in the
future to a true “disease-modifying therapy”. The peripheral nervous sytsem retains the
ability to repair itself, unlike the CNS, and likely may guide us toward new therapies for
neurodegenerative diseases and CNS trauma.
Our extensive transcriptomic analysis described in Chapter Three provides robust
scientific evidence of how a conditioning injury to the peripheral nerve drives the transdifferentiation of Schwann cells into “repair cells”. The trans-differentiation process
concurs with highly orchestrated changes in the levels of growth factors and repair
signaling molecules. Some of those released growth factors, such as GDNF, have already
shown efficacy in restoring and rescuing the structure and function of the dopaminergic
neurons in preclinical studies. Overall, PN tissue appears to have the capacity to promote
CNS plasticity and axon regeneration after an injury. We are aware that our transcriptional
analysis needs to be replicated and validated by other genomic and proteomic studies.
Nevertheless, we believe that our RNA-Seq analysis has helped to unmask key signaling
cascades that can promote the repair and restoration of the PNS. How we can utilize the
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capabilities of PN cells to minimize neuronal loss and induce axonal regeneration in
neurodegenerative diseases like PD now becomes a central question.
In Chapter Four, we detailed the establishment of the xenotransplantation animal
model, the Neuro-Avatar project. This project aimed to help us evaluate the neurobiology
of the sural nerve implants post-implantation in deep brain areas. We also reported the
long-term viability of the conditioned sural nerve implants in comparison to injury-naïve
PN implants. Survival and infiltration of the implanted human cells into the host brain were
assessed by staining for human nuclear antigen. We also employed proton MRS technique
to determine the brain reaction to the PN implant. Interestingly, we noticed an increase in
the neuronal integrity marker (NAA) around the implant. The main advantage of the in
vivo MRS study is that it can be safely translated to the DBS Plus clinical trial to evaluate
better the local effects of the implant on the metabolism and regeneration of the
surrounding midbrain neurons.
While the clinical trials that have investigated implanting PN cells/tissue into the
CNS are limited, those that have gone on to be published have demonstrated safety and
feasibility outcomes with some suggestion of potential clinical improvement. In the last
chapter of this dissertation, we tried to address the question of how the neurobiology of the
conditioned sural nerve implant will correlate with clinical outcomes. Up to two years postimplantation, the overall safety profile of combining DBS and autologous sural nerve
implantation into the substantia nigra is similar to that of the DBS surgery alone. None the
less, the preliminary analysis of the clinical outcome demonstrated very promising
improvements in the parkinsonian motor symptoms in response to the implant. An
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undergoing effort to enroll and collect UPDRS III data of participants who received only
the DBS procedure will help us better validate those preliminary clinical results.
In summary, the research described in this dissertation attempts to connect the dots
between basic science and clinical trials in the neurodegenerative fields. The findings of
these studies will significantly contribute to future translational studies in the areas of PNS
injury and CNS diseases. We believe that the cell-based therapies using transplantation of
autologous PN cells could become helpful in patients in the earlier stages of
neurodegenerative diseases when the CNS retains a reserve of functional cells and higher
“regenerative capacity.”
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